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ABSTRACT 
 
Introduction: Chronic moderate consumption of red wine (2-3 glasses/day) 
can protect against cardiovascular disease. However, the exact components 
which are found in the wine, and which are responsible for its cardioprotective 
effect, still remain to be delineated. The alcohol content and the polyphenol, 
resveratrol, are thought to contribute to this protection but the biogenic 
amines, melatonin and ethanolamine, recently identified in the composition of 
red wine, may also present some prosurvival properties.  
 
Aim: Therefore, the aim of our study was to explore whether resveratrol, 
alcohol, melatonin or ethanolamine, given chronically at the concentration 
equivalent as found in 2 glasses of wine/day, may protect the heart against an 
ischemia-reperfusion insult. Furthermore, we hypothesized that red wine and 
its cardioprotective components protect via the activation of the transcription 
factor signal transducer and activator of transcription 3 (STAT-3), a 
prosurvival factor known to protect against ischemia-reperfusion injuries. 
 
Methods: The drinking water of male Wistar rats was supplemented with a 
French Cabernet Sauvignon (12% or 6% alcohol by volume), alcohol (6%), 
resveratrol (7mg/L), ethanolamine (21µg/L) or melatonin (0.75µg/L), to a final 
concentration corresponding to the concentration found in 2 glasses of wine 
per day. After 10 days of treatment, hearts were perfused on the Langendorff 
system and subjected to 30 min global ischemia (I), followed by 60 min of 
reperfusion (R). Functional parameters were recorded throughout the 
experiments and infarct size was measured at the end of the protocol. Rate 
pressure product (RPP: heart rate x left ventricular developed pressure), 
measured at 60 min of reperfusion, was expressed as a percentage of 
baseline value. At the end of reperfusion, infarct size was recorded for all 
hearts. 
 
Results: Control hearts subjected to I/R presented a rate pressure product of 
20.5±4.5%. Pre-treatment with wine (6 or 12%) improved the rate pressure 
product to 40±6% and 43±6%, respectively (p<0.05 vs. control).  
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Neither resveratrol nor alcohol 6% given on their own improved the function of 
the heart, while ethanolamine and melatonin improved functional recovery to 
a similar extent to the wine (RPP: 33.9±6.7%, 30.6±2.3%, respectively p<0.05 
vs. control). Similarly, the pre-treatment with red wine, ethanolamine and 
melatonin decreased infarct size to (21.5±7.8%,19.0±6.9%, 27.5±7.8%, 
respectively p<0.05 vs. control). Interestingly, Western Blot analysis of the 
hearts show that pre-treatment with red wine, melatonin or ethanolamine were 
associated with an increase in STAT-3 phosphorylation, compared with the 
control groups (+70% for red wine, or +79% for melatonin and +57% 
ethanolamine). Furthermore, chronic administration of AG490, a STAT-3 
inhibitor abolished the protective effect of melatonin, ethanolamine or red 
wine.  
 
Conclusion: Our novel findings suggest that the biogenic amines, 
ethanolamine and melatonin, rather than resveratrol or the alcohol content in 
red wine, contribute to the cardioprotective effect of chronic moderate 
consumption of red wine and that this protective effect is mediated via the 
activation of STAT-3. Our findings may lead to the development of novel 
therapies to protect the heart against ischemia-reperfusion injuries.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Cardiovascular disease is a burden disease worldwide 
Cardiovascular disease (CVD) is responsible for more than 12% of worldwide 
mortality and it is predicted to become the leading cause of death by 2020, 
superseding infectious diseases such as Human Immunodeficiency Virus 
(HIV), tuberculosis (TB) and malaria (WHO 2009). CVD is a major concern in 
both developed and developing countries. In 2009, an estimated 785,000 
Americans will have a new coronary heart attack and about 470,000 will have 
a recurrent heart attack (Lloyd-Jones et al. 2009). In South Africa, CVD is 
already the number one killer in the Western Cape Province (= region around 
Cape Town; see figure 1) (Bradshaw et al. 2003). The main causes for heart 
disease in South Africa are uncontrolled hypertension and an urban lifestyle 
including inactivity and eating processed high salt foods. Eighty-eight percent 
of new heart failure patients in South Africa are black Africans with untreated 
high blood pressure (Steyn et al. 2005, Stewart et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A graphic representation of the burden of cardiovascular disease in the Western 
Cape region of South Africa. (Bradshaw et al. 2003) 
 
3000 2000 1000 0 1000 2000 3000
Ischaemic heart disease
Stroke
HIV/AIDS
Homicide/violence 
Tuberculosis
Road traffic accidents
Trachea/bronchi/lung cancer
COPD
Diabetes mellitus
Lower respiratory
Hypertensive heart disease
Suicide
Septicaemia
Nephritis/nephrosis
Breast cancer
Diarrhoeal diseases
Fires
Oesophageal cancer
Colo-rectal cancer
Stomach cancer
Males Females
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 2 
Coronary heart disease occurs when an atherosclerotic plaque accumulates 
and partially or wholly blocks a coronary artery. The formation of a blood clot 
(thrombus) inside a blood vessel obstructs the flow of blood through the 
circulatory system. This blockage leads to a reduction in the blood flow, 
nutrients, oxygen supply and vasoconstriction to an area of cardiac tissue. 
The area of tissue subjected to reduced flow in such conditions is referred to 
as ‘ischemic’ tissue and if left untreated, can result in cell death.  
 
The only way to salvage the heart is to restore the blood flow back (= 
reperfusion) into the ischemic area as quickly as possible in order to reduce 
the number of dead cells (forming the infarct) within the myocardium (see 
figure 2). This can be done with thrombolytic drugs or coronary angioplasty.  
 
The benefit of reperfusion, however, comes at a price. Paradoxically, the 
restoration of blood flow to the ischemic tissue often results in additional 
damage to the tissue, known as “reperfusion injury” (Grace 1994). This 
damage manifests itself as stunned myocardium, arrhythmias, endothelial 
damage and a significant increase of up to 50% of the final size of the infarct 
(Yellon, Hausenloy 2007). 
 
Additional therapies are required to limit the damage associated with coronary 
heart disease and recent evidence suggests that chronic and moderate 
consumption of red wine may protect the heart against cardiovascular 
disease. 
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 Figure 2: A graphic representation of myocardial infarction. 
 (From www.adam.about.com/encyclopedia/Acute. MI. html) 
 
1.2. Wine is a cardioprotective agent 
Although consumption of high amounts of wine (as well as other alcoholic 
beverages) remains a definite risk to health, consumption of lower amounts 
may not be harmful and even be considered as beneficial.  
 
1.2.1. The French paradox 
In 1979, St Leger and Colleagues were first to describe an inverse 
relationship between consumption of wine and deaths from cardiovascular 
disease in Europe, North America and Australasia (St Leger, Cochrane & 
Moore 1979a, St Leger, Cochrane & Moore 1979b). In 1992, Renaud and De 
Lorgeril emphasized the fact that a higher consumption of wine in France 
compared with other Western countries may contribute to explain the French 
Paradox, whereby French have a low coronary heart disease death rate 
despite high intake of dietary cholesterol and saturated fat (Renaud, de 
Lorgeril 1992).  
 
A study conducted in the Eastern part of France between 1978 and 1983 in 
more than 36 000 men, demonstrated that men drinking between 2 to 4 
glasses/day suffered 30% fewer deaths from all causes compared with non- 
drinkers or drinkers with more that 4 glasses/day (Renaud et al. 1999).  
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However, attributing the cardioprotective effect to the red wine leads to 
controversies as all the facets of wine drinkers’ behaviour cannot be summed 
up. Hence, differences in alcohol consumption may also reflect differences in 
nutritional intake. Indeed, wine drinkers consumed more fruits, salad, 
vegetables, fish and olive oil (Tjonneland et al. 1999). Also, wine drinkers 
exercise more (such as gardening), smoke less and they have a higher level 
of education (Mukamal et al. 2005a, Mukamal et al. 2005b). 
 
Also, the drinking pattern maybe of importance. Hence, a daily consumption 
of wine is associated with a better outcome than only occasional or weekend 
drinking (WHO, 2002). Drinking wine with food may also be of benefit as it 
slows the absorption of ethanol. 
 
1.2.2. Red wine vs. white wine vs. other alcoholic drinks 
In a Danish study conducted on more than 24 000 men and women living in 
Copenhagen, 1 to 3 glasses of wine intake reduced the risk of dying from 
cardiovascular disease by half compared with non-drinkers, whereas beer and 
spirit drinkers did not experience this advantage (Gronbaek 2000, Gronbaek 
et al. 2000). Similar data were found in a French study (Renaud et al. 1999) 
and in Northern California (Klatsky 2003, Klatsky et al. 2003). In contrast, type 
of alcohol made no difference to its protective effect on myocardial infarction 
in more than 38 000 participants in the US male health professions study over 
12 years of follow-up (Mukamal et al. 2003). In reality, data suggesting a 
better benefit of wine vs. beer may reflect the fact that wine drinkers have a 
better lifestyle than beer drinkers (Wannamethee, Shaper 1999). 
 
The unique protective effects of wine have been attributed to several 
polyphenols, especially resveratrol which is present in high concentration in 
red wine but not in white wine. This is explained by the fact that the grape 
skin, which contains a high concentration of polyphenols, is retained during 
the fermentation process of the red wine, while it is discarded for the white 
wine. Thus, the protective effect of red wine is suggested to be greater than 
white wine (van Velden, Mansvelt & Troup 2002).  
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However, several recent experimental studies indicate that white wine could 
have cardioprotective abilities similar to those of red wine and it is suggested 
that this cardioprotective effect is mediated by the presence of the 
polyphenols tyrosol and hydroxytyrosol (Dudley et al. 2008). 
 
1.2.3. Main physiological properties of red wine 
A regular consumption of red wine in humans (375 mL/day of red wine for 2 
weeks) is associated with a strong antioxidant effect (Fuhrman, Aviram 2001). 
This antioxidant effect may contribute to the cardioprotective effect of red wine 
by reducing the oxidative stress that occurs in various pathophysiological 
conditions such as ischemic heart disease, arteriosclerosis, heart failure, 
hypertrophy and arrhythmias (see review (Opie, Lecour 2007). Regular 
consumption of red wine reduces low density lipoproteins (LDL also called the 
“bad cholesterol”) and lipid peroxidation and increases plasma concentration 
of high density lipoproteins (HDL also called the “good cholesterol”) 
(Fuhrman, Lavy & Aviram 1995). In addition, the red wine modified and 
enriched the composition of HDL in polyunsaturated phospholipids such as 
omega-3 fatty acids, which are said to be beneficial against coronary artery 
disease (Perret et al. 2002). Red wine also inhibits smooth muscle cell 
proliferation in a dose-dependent manner, via the activation of 
phosphoinositol 3 phosphate kinase and p38 mitogen activated protein 
kinases (Araim et al. 2002). In addition, aggregation in response to adenosine 
diphosphate (ADP) and thrombin in human platelets is strongly inhibited by 
red wine (Pace-Asciak et al. 1995). 
 
1.2.4. Red wine and anti-ischemic properties 
In survivors of a recent myocardial infarction event, the association between 
red wine intake and the risk of recurrence during a 4-year follow-up 
demonstrated a reduction of the adjusted risk of cardiovascular complications 
by 59% in patients, with an average drinking of four glasses per day (de 
Lorgeril et al. 2002). 
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Chronic and moderate consumption of red wine is thought to contribute to 
cardioprotection and many experimental studies using the isolated rat heart 
model have explored the role of red wine against ischemia-reperfusion. 
However, all these studies were performed by giving acutely either red wine 
polyphenols extracts (Das et al. 1999) or some components of the wine such 
as resveratrol or ethanol (Ray et al. 1999b); see review (Das, Maulik 2006b). 
In the literature, none of the studies gave the original red wine orally, in 
conditions corresponding to a moderate and chronic consumption of red wine. 
Therefore, the relevance to a clinical setting of these studies is very limited. 
 
1.3. Cardioprotective components found in red wine 
Wine is a complex nutriment based on grape juice, in which alcohol has 
formed following natural fermentation. Wine contains more than 500 
compounds, some originating from the grapes and some metabolic by-
products of yeast activity during fermentation. Most of these compounds are 
present in very low concentrations, but a few occur at concentrations above 
100 mg/mL. These include water, alcohol, organic acids, sugars and glycerol 
(see figure 3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The main components of red wine. Theworldwidewine.com 
 
Here, we will review four compounds found in red wine and that we suggest 
may play a role in red wine-induced cardioprotection: alcohol, resveratrol, 
melatonin and ethanolamine. 
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1.3.1. Alcohol-induced health benefit 
The most important alcohol in wine is ethanol, with concentrations ranging 
from 10 to 14%. Ethanol is crucial for the stability, aging, and gustatory 
properties of the wine. It plays a role in the extraction of pigments and tannins 
during the fermentation of the skin and seeds of grapes (Das, Maulik 2006a) 
(Das et al. 1999). 
 
1.3.1.1. The J-shaped mortality curve 
Several epidemiological studies, the Framingham and Copenhagen City Heart 
trial, have shown that there is a consistent inverse relationship between 
alcohol consumption and mortality, whereby a low to moderate consumption 
of alcohol during meals promotes beneficial effects (Hulley, Gordon 1981, 
Thornton, Symes & Heaton 1983). However, the excessive consumption of 
alcohol or binge drinking increases the risk of mortality and disease (Gordon, 
Kannel 1984, Doll et al. 1994, Thun et al. 1997) and the alcohol effect can be 
described as a J-shaped curve (see figure 4). It is recommended for men and 
women to have 2 to 3 glasses of alcohol per day to confer cardioprotection 
and teetollars have neither an increased nor a decreased risk of CVD 
(Thornton, Symes & Heaton 1983). 
 
In a multinational study, lack of alcohol intake increased risk factors for type 2 
diabetes, emphasizing that cardioprotection conferred from alcohol 
consumption affects triglycerides and insulin levels (Hu et al. 2001). However, 
the cessation of alcohol will result in the loss of all beneficial effects within 24 
hours (Jackson, Scragg & Beaglehole 1992). The ill effects of binge drinking 
counter the inverse proportion of cardioprotection for moderate drinkers who 
consume alcohol with meals. However, there is no relationship with alcohol 
consumption during meals in American men who predominantly consume 
beer and liquor (Kozarevic et al. 1983).  
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Figure 4: A graphic representation of the J-shaped mortality curve illustrating that the 
moderate consumption of alcohol has been shown decrease the risk of mortality, but high 
levels of alcohol consumption has the adverse effects (Adapted from Gordon and Kannel, 
1984).  
   
1.3.1.2. Mechanisms involved in alcohol-induced cardioprotection  
Moderate alcohol consumption, 1 drink or less per day for women and 2 
drinks or less per day for men, has been found to reduce the incidence and 
adverse consequences of heart disease in several epidemiological studies, 
see review (Mukamal et al. 2006). There is a great focus on the identification 
of intracellular signalling pathways activated by moderate alcohol 
consumption that preserve viability and contractility of the cardiac tissue. Adult 
rodent protocols have been performed to simulate human drinking patterns to 
test whether moderate alcohol intake could protect the heart against I/R injury. 
In these studies, moderate alcohol consumption-sustained cardioprotection 
required the activation of the mitochondrial KATP channels, see review (Collins 
et al. 2009). Mice treated with 10% alcohol for 12 weeks protected the hearts 
against ischemia reperfusion injury via the activation of NO (Zhou, Karliner & 
Gray 2002b). Similarly, rats that were treated with 18% alcohol for 8 weeks in 
drinking water improved post-ischemic systolic and diastolic pressure and it 
also reduced cardiovascular resistance via the activation of protein kinase C 
(PKCε), see review (Collins et al. 2009).  
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1.3.1.3. Alcohol free wine can confer cardioprotection 
The contribution of alcohol in red wine-induced cardioprotection is questioned 
by studies performed on de-alcoholized red wine. In patients with coronary 
artery disease, 250 mL of de-alcoholized Greek red wine decreased arterial 
stiffness (Zilkens et al. 2005). Similarly, brachial artery flow-mediated 
vasodilation was improved after drinking de-alcoholized red wine (Rosenkranz 
et al. 2002) or grape juice (Cruz et al. 2006). Also, grape juice and red wine 
reduced LDL susceptibility to oxidation while ethanol failed to do so (Cruz et 
al. 2006). Therefore, these data strongly suggest a cardioprotective effect of 
red wine beyond alcohol.  
   
1.3.2. Resveratrol induced health benefit  
The richest source of resveratrol and its analogs occur naturally in many plant 
species, including berries, grapevines and the roots of Polygonum cuspidatum 
cultivated in China and Japan. Resveratrol (3,4,5-trihydroxy-trans-stilbene) is  
a phytoalexin and has been reported to exhibit a wide range of biological and 
pharmacological properties. It has been speculated that dietary resveratrol 
could be an explanation for the so-called 'French paradox' as it may act as a 
cardioprotective agent via its antioxidant properties promoting nitric oxide 
production, inhibiting platelet aggregation and increasing HDL cholesterol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The molecular structure of resveratrol  
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1.3.2.1 Resveratrol and wine 
Both isoforms cis and trans-forms of resveratrol exist in wine. It is believed 
that they are in equilibrium and exhibit similar biological properties. However, 
there are varying concentrations of resveratrol in different wines. A possible 
reason for this is that resveratrol is synthesized in response to environmental 
stressors, which include water deprivation, UV radiation and fungal infection, 
see review (Das, Maulik 2006a). Resveratrol is one of the several stilbenes 
found in wine and probably the most researched. The consumption of half a 
bottle of Brazilian red wine containing a stilbene of 11mg/mL would result in a 
blood concentration of between 4µmol/L and 10µmol/L, see review (Opie, 
Lecour 2007). The concentration of 10µmol/L is the minimum resveratrol 
concentration required to exert a biological effect in vitro (Pellegatta et al. 
2003). This study raises the possibility that therapeutic resveratrol levels could 
be reached by consuming red wine. 
 
Table 1: Different types of red wine, their countries of origin and their content in resveratrol 
adapted from (see review: Opie and Lecour, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.5 mg/L–Red grape juice
18.0 mg/LBrazilRed, varietal not 
stated
5.0–12.3 mg/LSwitzerlandRed, varietal not 
stated
3.9 mg/LFranceBordeaux reds
3.6 mg/LFranceRhone valley reds
0.9 mg/LCaliforniaCabernet Sauvignon
1.7 mg/LAustralianCabernet Sauvignon
5.1 mg/LSpanishPinot noir
4.4 mg/LBurgundyPinot noir
5.5 mg/LCalifornianPinot noir
13.4 mg/L=59 µmol/LAustralianPinot noir
Resveratrol
concentration
Country of 
origin
Wine varietal
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1.3.2.2 Main physiological properties of resveratrol 
a) Antioxidant properties 
Resveratrol is responsible for scavenging intracellular reactive oxygen 
species (ROS).  Although it possesses antioxidant properties in vivo, it is a 
weak scavenger in vitro (Bhat, Kosmeder & Pezzuto 2001). This antioxidant 
effect could explain the inhibition of LDL oxidation (Frankel et al. 1993). 
Furthermore, resveratrol has the ability to inhibit intracellular adhesion 
molecule (ICAM) and nuclear factor beta (NFkB) which is an indirect marker 
for oxidative stress (Leonard et al. 2003). The activation of NFkB by tissue 
necrosis factor alpha (TNFα) is attenuated by resveratrol administration 
(Leonard et al. 2003). Furthermore, resveratrol inhibits angiotensin–induced 
hypertrophy. This effect is also thought to be related to its antioxidant 
properties because the inhibition is associated with a reduced production of 
ROS, see review (Das, Maulik 2006a). 
 
b) Metabolic properties 
Resveratrol has the ability to shift the physiology of middle-aged mice fed with 
a high caloric diet towards that of the mice on a standard diet and significantly 
increase their survival (Baur et al. 2006). Interestingly, the metabolic effects of 
resveratrol include an increased insulin sensitivity,  reduced insulin-like growth 
factor-1 (IGF-1) levels, increased adenosine monophosphate  activated 
kinase (AMPK) and perioxisome proliferator activator receptor γ coactivator 
1α (PGC-1 α) activity with increased mitochondrial number and improved 
motor function, see review (Opie, Lecour 2007). 
 
c) Anti-aging properties 
Resveratrol is the only molecule that consistently prolongs lifespan across all 
species (Wood et al. 2004, Viswanathan et al. 2005). The polyphenol has 
increased lifespan of yeast C elegans and Drosophilia, see review 
(Valenzano, Cellerino 2006a). The administration of resveratrol directly mixed 
with the daily food of fish starting after the 4th week of life extended from 27 
weeks to 59 weeks until death (Valenzano, Cellerino 2006a). Resveratrol 
induced dose-dependent life extension. Furthermore, resveratrol retarded the 
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onset of age-dependent cognitive function and locomotive deficit and 
prevented the neuro-degeneration (Valenzano et al. 2006b). 
 
1.3.2.3 Resveratrol and the cardiovascular system 
a) Vascular properties 
Nitric oxide (NO) is a key player in vasorelaxation. When less oxygen is 
available in the cell, trans-resveratrol will have vasorelaxing properties on the 
endothelium of the heart. In the pulmonary artery, a high secretion of NO is 
detected but, when the endothelium was removed, vasorelaxation was lost 
with resveratrol, implying that resveratrol confers cardioprotection via NO 
(Cishek et al. 1997). Resveratrol increases 3,5-guanosine-monophoposphate 
(cGMP) with an increase in nitric oxide in cultured pulmonary endothelial cells 
(Klinge et al. 2003). In the presence of a NO inhibitor, monomethyl-L-arginine 
and N-G-methyl-L-arginine, in the working rat heart model, and resveratrol no 
longer conferred cardioprotection against ischemia reperfusion (Hattori et al. 
2002).  
 
b) Anti-ischemic properties 
Several studies conducted on the isolated rat heart model and in vivo have 
demonstrated that resveratrol has the ability to protect the ischemic 
myocardium through NO activation (Hattori et al. 2002). Hence, 
preconditioning the heart with 2.3mg/L of resveratrol given prior to the 
ischemic insult, provided cardioprotection as evidenced by improved 
postischemic ventricular recovery, reduced infarct size, and decreased 
cardiomyocyte apoptosis (Hattori et al. 2002). This effect is mediated via a 
reduction in reactive oxygen species. Interestingly, inducible nitric oxide 
synthase (iNOS) knockout mouse hearts could not be preconditioned with 
resveratrol (Imamura et al. 2002). Also, resveratrol (2.3mg/L), given before a 
30 min ischemia and 2 hours reperfusion insult,  protects the heart through 
increased expression of adenosine A1 and adenosine A2 receptor (Das et al. 
2005). Resveratrol induced the expression of anti-apoptotic Bcl-2 along with 
the phosphorylation of cyclic AMP response element binding protein, Akt and 
Bad, see review (Das, Maulik 2006b). These results indicate that resveratrol 
pharmacologically preconditions the heart via the activation of prosurvival 
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pathways. Recent studies have also demonstrated that resveratrol protects 
the heart against reperfusion injury (Xi et al. 2009). In isolated rat hearts 
exposed to 30 min ischemia and 2 hours reperfusion, the resveratrol given at 
the onset reperfusion, enhanced glycogen synthase-3β (GSK-3β) 
phosphorylation and its translocation from the cytosol to mitochondria by 
targeting the inhibition of the mitochondrial permeability transition pore 
(mPTP) (Xi et al. 2009). However, the concentration of resveratrol used in 
these experiments is far higher than the quantity of resveratrol given by 
consuming 2 glasses of red wine per day. In addition, no experiments have 
shown a cardioprotective effect of resveratrol by chronically administering 
resveratrol at an equivalent concentration to the concentration found in red 
wine. There is no evidence that strongly suggests that resveratrol can account 
for the cardioprotective effect of red wine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic representation of the proposed cardiovascular mechanisms of 
resveratrol. HDL=high density lipoproteins, LDL=low density lipoproteins. Adapted from Das 
et al., 2006 
 
1.3.3. Melatonin induced health benefit  
In 2006, melatonin was identified as another phytochemical present in grapes 
(Iriti 2009). Melatonin, also known chemically as N-acetyl-s-
methoxytryptamine, is a naturally occurring hormone found in humans.  
 
 
Cardioprotection 
by resveratrol
Antioxidant 
effect
Vasorelaxation
Prevents 
inflammation
Prevents 
platelet 
aggregation
Reduction in 
Ischemia-reperfusion injury
Increases HDL
Decreases LDL
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Its main function in the body is to control the body’s circadian rhythm (Kumar, 
Singh 2009) and to regulate other hormones (i.e. female reproductive 
hormones) (Girgert et al. 2009). It has strong antioxidant properties that may 
contribute to its cardioprotective effect (Tan et al. 1993). 
 
 
 
 
 
 
 
 
 
 
Figure 7: The molecular structure of melatonin.  
 
  
1.3.3.1 Melatonin and wine 
Melatonin is synthesised by various plants such as rice. In 2006, Italian 
researchers found the presence of melatonin in extracts from different wine 
grapes including Nebbiolo, Croatina, Sangiovese, Merlot, Mrzemino, Cabernet 
Franc, Cabernet Sauvignon and Barbera. Melatonin was found in a high 
concentration in red wine ranging from 50pg/mL to 200pg/mL. Interestingly, 
the amount of melatonin is lower in white wine (range: 10-50pg/mL) and even 
less in liquors (range: 5-20pg/mL) (Guerrero et al. 2008). It is likely that 
cultivar, agro-meteorological conditions (Burkhardt et al. 2001), vintage and 
wine-making procedures contribute to the difference in concentration of 
melatonin between the wines (Burkhardt et al. 2001). Ironically, the anti-mould 
fungicide benzothiadiazole, which wineries spray on their plants to protect the 
grapes, seems to increase the concentration of melatonin (Burkhardt et al. 
2001). 
 
Interestingly, Guerrero et al. 2008 demonstrated that serum melatonin was 
significantly increased in humans, one hour after an intake of 100 mL of red 
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wine. However, for unknown reasons, this article has been withdrawn at the 
request of the editor.  
  
 
 
 
 
 
 
 
 
 
Figure 8: Melatonin concentrations found in differing alcoholic beverages: red wine, white 
wine and liquors (Guerrero et al. 2008).  
 
1.3.3.2 Biosynthesis of melatonin 
Melatonin is produced by pinealocytes in the pineal gland and also by the 
retina, lens, gastrointestinal tract and other tissues such as the skin (Karasek, 
Winczyk 2006). It is synthesised from the amino acid tryptophan (via 
synthesis of serotonin). Serotonin is converted to melatonin in the presence of 
N-acetyltransferase and s-acetylserotonin-O-methyltransferase (ASMT). Its 
production by the pineal gland is regulated by the hypothalamus which 
receives information from the retina about the daily pattern of light and 
darkness. Light suppresses the production of melatonin while darkness 
stimulates its production. Exposure to excessive light in the evening or too 
little light during the day can disrupt the body’s normal melatonin cycle.  
 
The mean production rate of endogenous melatonin has been calculated as 
30µg per day with a half-life of 30-60 min, see review (Karasek, Winczyk 
2006). 
 
1.3.3.3 Physiological properties of melatonin 
Since its discovery in 1958, many biological functions have been attributed to 
melatonin and most of its effects are produced through the activation of the 
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melatonin receptors. Melatonin acts through a series of targets, melatonin 
receptor 1, 2 or 3 (MT-1, 2, 3) (Mailliet et al. 2005) and its cardioprotective 
effect is suggested to be dependent of receptors 1 and 2 (Genade et al. 
2008). In the heart and in the arteries, melatonin receptors were discovered in 
2002 (Pang et al. 2002, Masana et al. 2002). Melatonin forms part of the 
system that regulates the circadian cycle by chemically causing drowsiness 
and lowering the body temperature.  
 
In 1993, powerful antioxidant properties of melatonin were discovered (Tan et 
al. 1993). Melatonin, a lipid- and water-soluble compound, easily and rapidly 
enters all cells and subcelullar compartments, including the nuclei and 
mitochondria (Karbownik, Reiter 2000). Melatonin can act as a free radical 
scavenger by directly scavenging reactive oxygen species and reactive 
nitrogen species, see review (Tengattini et al. 2008). Hence, melatonin can 
neutralize the highly toxic hydroxyl radical (.OH) to generate the product 
cyclic-3-hydroxymelatonin (Karbownik, Reiter 2000) Melatonin can also 
neutralize the superoxide anion radical (Reiter et al. 2001), the hydrogen 
peroxide (Tan et al. 2000), the nitrogen monoxide (Mahal, Sharma & 
Mukherjee 1999) and peroxynitrite (Srinivasan 2002), but the mechanisms 
remain unclear. Beside its free radical scavenging properties, melatonin has 
the ability to regulate the antioxidant enzyme activities such as superoxide 
dismutase, catalase, and glutathione peroxidase, see review (Tengattini et al. 
2008). Both melatonin receptors (MT1 and MT2) seem to be involved in this 
indirect antioxidative effect (Tomas-Zapico, Coto-Montes 2005). Interestingly, 
melatonin may also regulate the activity of pro-oxidative enzymes such as 
nitric oxide synthase (Karbownik, Reiter 2000). 
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Table 2: The different types of ROS/RNS/enzyme and the respective effect of melatonin. 
Adapted from (Tengattini et al., 2009). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
The antioxidant properties of melatonin may reduce damage caused by some 
type of Parkinson’s disease and it may increase longevity (Jung-Hynes, 
Ahmad 2009). Melatonin acts as an endogenous sleep-inducing agent and 
reduced concentration may result in lowered sleep propensity which is 
associated with advanced aging. Decreased melatonin results in the inhibition 
of longevity protein sirtuin-1 (SIRT1) which has an antiproliferative response 
in aging via the resynchronization of the circadian clock (Jung-Hynes, Ahmad 
2009).  
The activation of the melatonin’s receptors may play a role in the process of 
learning and memory and the treatment of melatonin may decrease the 
evolution of cognitive impairment in Alzheimer patients (Olcese et al. 2009).  
 
Recent data also suggest that deficiency in melatonin may be involved in the 
pathology of autism spectrum disorders (ASD).  
↓Lipo-oxygenase
↓Nitric oxide synthase
Pro-oxidative enzymes
↑Gamma-glutamylcysteine synthase
↑Glucose-6-phosphate dehydrogenase
↑Glutathione reductase
↑Glutathione peroxidase
↑Catalase
↑Superoxide dismutase
Antioxidative enzyme
↓Peroxynitrite anion
↓Nitric oxide
↓Singlet oxygen
↓Hydroxyl radical
↓Hydrogen peroxide
ROS/RNS
Effect of melatoninROS/RNS/enzyme
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Parents of autistic patients have a lower level of melatonin associated with a 
lower activity of the ASMT gene, which encodes for the last enzyme of 
melatonin synthesis (Galli-Carminati, Deriaz & Bertschy 2009, Golnik, Ireland 
2009). 
 
Melatonin may play an important role in metabolic regulations of the body. 
After activation of its membrane receptor 1 (MT1), melatonin activates insulin 
receptors and upregulates insulin-stimulated leptin expression (Alonso-Vale et 
al. 2005).  
 
1.3.3.4 Melatonin and the cardiovascular system 
a) Melatonin and blood pressure 
Hypertension is one of the most prevalent risk factors for cardiovascular 
disease (Steyn et al. 2005, Stewart et al. 2006). The effect of melatonin on 
blood pressure is paramount. Pinealectomy rats have decreased levels of 
melatonin associated with vasoconstriction and temporary hypertension. 
However, the administration of melatonin in these animals reversed the 
effects (Zanoboni, Zanoboni-Muciaccia 1967). Interestingly, continuous 
exposure to light both day and night prevents the nocturnal increase of 
melatonin, suppresses circadian heart rate and augments blood pressure, 
resulting in melatonin deficient hypertension.  Spontaneous hypertensive rats 
with left ventricular hypertrophy were treated with melatonin, which improved 
cardiac function but did not alter the left ventricular relative weight (Zanoboni, 
Zanoboni-Muciaccia 1967). These results strongly suggest that melatonin 
plays a major role in the regulation of hypertension. 
 
b) Melatonin and atherosclerosis 
Atherosclerosis is the abnormal development and progression of cholesterol 
deposits in the tunica intima of arteries. The development of the plaque 
involves the activation of inflammatory cytokines and oxidized LDL, (Pieri et 
al. 1996). Melatonin inhibits oxidized LDL in vitro in a dose-dependent manner 
(Duell et al. 1998).  
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Other studies support these findings and suggest that melatonin precursors 
(such as L-tryptophan and serotonin) as well as the breakdown products 
(such as niacin or quinolinate) also inhibit oxidation of LDL (Pieri et al. 1996).  
Melatonin reduces the total cholesterol plasma levels and decreases very low-
density lipoproteins, (VLDL) in hypercholesterolemic rats (Kelly, Loo 1997).  
 
c) Melatonin and ischemia/reperfusion 
(i) Acute administration 
In 1998, Tan and Colleagues used an isolated heart model to demonstrate 
that concentrations of melatonin ranging from 1-50µM, protected the heart 
against ischemia reperfusion-induced arrhythmias, including decreasing the 
severity and reducing their incidence and duration (Tan et al. 1998). 
Interestingly, this protective effect was more potent than the well-known 
antioxidant vitamin C.  
 
Administration of melatonin also protected the isolated rat heart by reducing 
ventricular fibrillation and partially restoring ventricular function (Kaneko et al. 
2000). This protection was associated with the reduction in free radicals 
released and a decrease in lipid peroxidation (Kaneko et al. 2000). Melatonin 
(1 or 10mg/kg; ip), given to rats 30 min prior to an ischemia-reperfusion in 
vitro, reduced infarct size (Lagneux et al. 2000). The protective effect of 
melatonin proposed to be mediated via its antioxidant effect on intracellular 
calcium accumulation (Salie et al. 2001). Melatonin-induced protection is also 
associated with the activation of Akt and inhibition of the pro-apoptotic kinase, 
p38MAPK during early reperfusion (Genade et al. 2008). Furthermore, 
melatonin possesses an anti-adrenergic action via nitric oxide synthase and 
guanylyl cyclase activations (Genade et al. 2008). 
 
(ii) Chronic administration 
A chronic treatment with melatonin has the ability to reduce infarct size 
(Lochner et al. 2006). The long term effects of melatonin were evaluated 24 
hours after melatonin administration (2.5 or 5.0 mg/kg, ip) or after the oral 
supplementation of melatonin in the drinking water for 7 days (20 or 40µg/mL) 
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(Lochner et al. 2006). The results obtained suggested that melatonin induces 
long-term protection evidenced by the reduction of infarct size.  
The cardioprotective effect of melatonin persisted for 2-4 days after 
discontinuation of treatment.   
However, these concentrations used in these studies are superior to the 
concentration of melatonin that would be found in regular consumption of 2 
glasses of wine per day (concentration of melatonin in red wine = 0.75µg/L) 
and no studies have explored whether melatonin from wine may contribute to 
the cardioprotective effect of regular consumption of red wine. 
 
1.3.4. Ethanolamine induced health benefit 
Ethanolamine, also called 2-aminoethanol or monoethanolamine, is an 
organic compound that is both a primary amine (due to the amino group in its 
molecule) and a primary alcohol (due to a hydroxyl group). 
 
1.3.4.1. Ethanolamine and wine 
Exogenous ethanolamine can be obtained from many foods and beverages 
including wine (Hernandez et al. 2007) and soya products (Imaizumi et al. 
1989). It is found in both red and white wine, at a concentration ranging from 
4.5 to 7 µg/L in white wine and from 13.5 to 25 µg/L (mean concentration of 
21µg/L) in red wines (Hernandez et al. 2007), but these concentrations may 
vary during wine aging, the climate, the type of soil, the type of grapes and the 
fermentation process used (Jimenez Moreno, Torrea Goni & Ancin Azpilicueta 
2003). Hence, certain types of yeasts used for the fermentation process will 
influence the formation of ethanolamine more than other type of yeasts 
(Jimenez Moreno, Torrea Goni & Ancin Azpilicueta 2003). 
 
 
 
Figure 9: The molecular structure of ethanolamine.   
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1.3.4.2. Physiological properties of ethanolamine 
In the body, little is known about the physiological properties of ethanolamine. 
This biogenic amine is synthesized as a downstream product of anandamide 
(an endogenous cannabinoid), in the presence of the enzyme fatty acid amine 
hydrolase (FAAH).  
 
Ethanolamine stimulates the phospholipids synthesis such as 
phosphatidylethanolamine, phosphatidylcholine and sphingomyelin, major 
constituents of the phospholipid membrane (Sundler, Akesson 1975).   
 
The presence of ethanolamine in the circulation is thought to act as a humoral 
hepatotrophic factor in the early stages of liver regeneration following 
hepatectomy (Kume, Sasaki 2006, Kume, Sasaki & Kano-Sueoka 2006).  
 
Recent evidence suggests that ethanolamine may have anti-cholesterol 
properties. Interestingly, hypercholesterolemic rats fed with a high fat/high 
cholesterol diet and water containing up to 1mg/mL of ethanolamine, 
decreased VLDL cholesterol and LDL cholesterol in a dose dependent 
manner (Kume, Sasaki 2006). Levels of serum HDL cholesterol levels 
remained unchanged. The anti-hypercholesterolemic effect of ethanolamine is 
suggested to be mediated via the downregulation of ApoB in the liver (Kume, 
Sasaki 2006). In brain cells, ethanolamine can protect from low serum-
induced apoptosis via inactivation of the caspases 3/7 activities (Matas et al. 
2007).  
 
1.3.4.3. Ethanolamine and the heart 
No previous studies have explored the role of ethanolamine in the heart. 
However, anandamide, the precursor of ethanolamine’s formation in the body, 
can protect the isolated heart against coronary occlusion. Hence, anadamide 
(1µM), given 5 min before ischemia until the end of reperfusion, reduced the 
infarct size (Underdown, Hiley & Ford 2005). This effect is suggested to be 
partly mediated via a cannabinoid receptors-independent pathway 
(Underdown, Hiley & Ford 2005) and therefore may involve ethanolamine. 
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Further studies are necessary to delineate the exact mechanisms involved in 
the protective effect. 
 
1.4. The JAK/STAT-3 pathway protects against ischemia-reperfusion 
The Janus kinase / Signal transducer and activator of transcription-3(STAT-3) 
pathway is a novel signal transduction pathway which, upon its action, 
activates numerous genes, see review (Lecour 2009a, Lecour 2009b). In the 
heart, the activation of this pathway has been implicated in cardiac 
hypertrophy (Kurdi, Booz 2007) and ischemia-reperfusion (Lecour et al. 
2005b); see review (Lecour 2009a, Negoro et al. 2000, Omura, Yoshiyama & 
Yoshikawa 2000). 
 
1.4.1. Definition of the JAK/STAT-3 pathway  
STAT are a family of cytoplasmic transcription factors mediating intracellular 
processes that are activated by cytokines at the surface receptor. There are 
several known relatives to the STAT family, STAT1, STAT2, STAT-3, STAT4, 
STAT5a, STAT5b and STAT6. In the heart, STAT activity is limited to STAT1 
and STAT-3 (McCormick et al. 2006). STAT1 has been demonstrated to have 
apoptotic effects, whereas STAT-3 is involved in cardioprotection (Hattori et 
al. 2001). STAT-3 activation can occur when a cytokine binds to a specific 
receptor activating Janus Kinases-2 (JAK2) or mitogen activating protein 
kinases (MAPK). Upon its phosphorylation, STAT-3 will form dimers and 
translocate to the nucleus. Studies have shown that STAT-3 can also 
translocate to the mitochondria after phosphorylation on the tyrosine site. 
Hence, in heart mitochondria isolated from STAT-3 deficient mice the activity 
of complex І and ІІІ of the electron transport chain (ETC) was decreased. The 
mitochondrial respiration was altered with a decrease in complex І and ІІІ 
activity of the ETC (Gough et al. 2009, Wegrzyn et al. 2009). 
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Figure 10: Schematic representation of the JAK-STAT pathway (adapted from Cell Signalling 
catalogue 2007). 
 
1.4.2. JAK/STAT-3 pathway protects against ischemia-reperfusion 
The activation of STAT-3 following  myocardial infarction was first 
demonstrated in 2001, with an increase in phosphorylation of STAT-3  which 
was observed up to 24 hours after ligation of the left coronary artery of rats 
(Xuan et al. 2001, Yang et al. 2008).Transgenic mice with cardiac specific 10 
fold over-expression of STAT-3 had significantly reduced infarct size after 1 
hour ischemia and 2 hours of reperfusion as well as another set of transgenic 
mice exposed to 30 min ischemia followed by 24 hours reperfusion compared 
to non-transgenic mice(Xuan et al. 2001, Yang et al. 2008).  A key role for the 
JAK/ STAT signalling pathway has been demonstrated in ischemia and 
pharmacological preconditioning (Xuan et al. 2001, Lecour et al. 2005a) and 
postconditioning (Lacerda et al. 2009, Boengler et al. 2008a) see review 
(Boengler et al. 2008b).  
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1.4.3. Possible downstream targets of JAK/STAT-3  
Downstream effectors of the JAK/STAT-3 pathway target the mitochondrial 
potassium channel (K/ATP/) (Mykytenko et al. 2008). The opening of the 
mitochondrial permeability transition pore in the inner membrane of the 
mitochondria is responsible for the uncoupling of proteins, the efflux released 
from cytochrome c and several other apoptotic factors that eventually lead to 
cell death (Hausenloy, Yellon 2003, Hausenloy, Duchen & Yellon 2003).  
There are several other downstream targets that have been identified 
including proteins that are involved in cell survival and proliferation such as 
Bcl-2, Bcl-xL, Mcl-1, Fas, p21 and growth factors like VEGF. STAT-3 plays a 
crucial role in a preconditioning setting by reducing the pro-apopototic factors 
such as Bax and Bad and enhances the activation of Bcl-2 see review (Lecour 
2009a, Lecour 2009b). 
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1.5. Objectives of the study 
 
 AIM 
The aim of our study was to explore whether resveratrol, alcohol, 
melatonin or ethanolamine, given chronically at the concentration 
equivalent as found in 2 glasses of wine/day, may protect the heart 
against an ischemia-reperfusion insult.  
 
Furthermore, we hypothesized that red wine and its cardioprotective 
components protect via the activation of the transcription factor signal 
transducer and activator of transcription 3 (STAT-3), a prosurvival factor 
known to protect against ischemia-reperfusion injuries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Hypothetical protective pathway of red wine induced protection mediated by 
melatonin and ethanolamine via the activation of the JAK/STAT-3 pathway.  
 
 
 
 
ethanolamine Melatonin
alcohol resveratrol
? ?
STAT -3 activation
P
P
STAT
STAT
P
P
nucleus
Cardioprotection
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 26 
To investigate this aim, Wistar rats were pre-treated for 10 days with a French 
Cabernet Sauvignon, resveratrol, alcohol, melatonin or ethanolamine (given at 
the concentration equivalent as the concentration found in 2 glasses of 
wine/day) and their hearts were subjected to an ischemia-reperfusion insult 
using the Langendorff perfusion system.  The role of the JAK/STAT-3 
pathway was studied using AG490, the JAK/STAT-3 pathway inhibitor and 
STAT-3 activation will be assessed by Western Blot technique. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1       Animals 
All the experiments were conducted on male Wistar rats weighing 230-300g 
and were performed in accordance with the Guide for Care and Use of 
Laboratory animals published by the U.S. National Institutes of Health (NIH 
pulblication No. 85(23), revised 1996). All procedures were approved by the 
Animal Research Review Committee of the University of Cape Town 
(applications; 008/026 entitled “Delineation of mechanisms for wine-induced 
cardioprotection”, 007/012 “Delineation of resveratrol-induced 
cardioprotection” and 005/016 “The cardioprotective effect of alcohol-free 
wine”). 
 
2.2     The Langendorff perfused isolated rat heart model 
Rats were anaesthesized with 60 mg/kg intraperitoneal sodium 
pentobarbitone mixed with 200I.U. heparin. Hearts were excised rapidly, 
cannulated via the aorta, and perfused retrogradely using the Langendorff 
perfusion system at a constant pressure (100 cm H20), at 37ºC, with Krebs-
Henseleit buffer equilibrated with 02/CO2 95:5%. The following composition of 
the Krebs- Henseleit perfusion buffer as follows in mM: (118.0 NaCl, 25.2 
NaHCO3, 4.7 KCl, 1.2 MgSO4.7H2O, 1.2 KH2PO4, 1.2 CaCl.2H20, and 11.0 
Glucose, pH of 7.4).  
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Figure 12: A graphic representation of retrograde perfusion in Langendorff mode 
(ADInstruments, London) 
 
 A balloon was inserted through the left atrium into the left ve tricle and the 
left ventricular end diastolic pressure was adjusted between 4 and 12mmHg. 
Cardiac parameters were monitored throughout the experiments and included 
heart rate (HR), left ventricular developed pressure (LVDP: difference 
between left ventricular end systolic pressure (LVESP) and end diastolic 
pressure (LVEDP) and the coronary flow (CF). Rate pressure product was 
expressed as LVDP X HR. 
 
 
Figure 13: Schematic representation of the balloon catheter (ADInstruments, London). 
 
Exclusion criteria 
Rats that did not comply with the following criteria were removed from the 
study:  
(1) Left ventricular pressure must be higher than 80mmHg. 
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 (2) Coronary flow must be a minimum of 8mL/min and a maximum of 
16mL/min. 
(3) Heart rate should be a minimum of 240beats/min and a maximum of 400 
beats/min. A total of 10 out of 144 rats were excluded from the study.  
 
2.3     Langendorff perfusion protocols  
2.3.1. Chronic study 
French Cabernet sauvignon was used in this study. The alcohol was removed 
by the lirisation® process and oenological expertise from approximately 12% 
alcohol by volume to a final concentration of 6% alcohol by volume. The 
lirisation® process presents the advantage of lowering the alcohol content of 
the original wine without any other alteration of the original composition of the 
wine. The drinking water used for controls was supplemented by wine (12%), 
wine (6%), alcohol (6%), resveratrol (check7mg/L), melatonin (0.75µg/L) or 
ethanolamine (21µg/L) before the dilution for 10 days. The different solutions 
were prepared by adding one part of red wine or drug solution to seven parts 
drinking water. Since the rats drank an average of 30mL/day and the final 
concentration received was the following: wine (1.50%), wine (0.75%), alcohol 
(0.75%), resveratrol (0.8mg/L), melatonin (0.94µg/L) or ethanolamine (2.60 
µg/L).  When the drugs were given, both body weight and the amount of 
drinking water consumed by each rat were taken into account to ensure that 
the amount given per day corresponded to an equivalent of 2 glasses of 
wine/day which would mimic the reality. Luzindole (5mg/kg/day), a melatonin 
receptor 1 and 2 antagonist, or AG490 (5mg/kg/day), a JAK-2 antagonist, was 
administered intraperitonelly once a day for 10 days. Thereafter, the rat hearts 
were removed and mounted onto the Langendorff perfusion system. All hearts 
were equilibrated for a period of 30 min and were consequently subjected to 
either 30 min global or regional ischemia followed by 30 min of reperfusion 
which was later increased to 60min reperfusion for improved visualisation of 
the infarct size. Global ischemia was used for all the chronic studies and was 
obtained by a cessation of perfusate together with additional KHB within the 
jacket to stabilise the temperature at 37ºC.  
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The functional parameters of the heart were monitored (LVEDP, LVESP, 
LVDP, heart rate and coronary flow). A preliminary study was performed to 
ensure that the amount of beverage drink/ day was unchanged with the 
addition of drug or wine.   
 
 
 
 
 
S=stabilisation, GI=Global Ischemia, R= Reperfusion 
 
2.3.2. Acute study 
In a Langendorff perfusion system, all rat hearts were equilibrated for 30 min 
and consequently subjected to a standard 30 min of regional ischemia which 
was used for all the acute studies. In regional ischemia, a 3/0 silk suture was 
placed around the left coronary artery to form a snare. After the occlusion, the 
heart was reperfused for 120 min. Melatonin (0.75µg/L), ethanolamine 
(21µg/L) or resveratrol (2.30mg/L) at the concentration found in wine were 
perfused for 15 min followed by 10 min wash out period before regional 
ischemia. Additional groups were perfused with AG490 (100 nM), a STAT-3 
inhibitor. AG490 was perfused for 3 min on its own followed by a 15 min co-
administration with melatonin, ethanolamine or resveratrol followed by a 
further 5 min of AG490 alone and 10 min wash-out prior to regional ischemia 
(RI). 
 
 
 
 
 
S=Stabilisation, WB= Western Blots, RI= Regional Ischemia, R= reperfusion 
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2.4 Different perfusion protocols 
Group 1: Role of chronic moderate consumption of red wine for (10 days) 
protects against ischemia reperfusion injury (I/R) (Endpoint = Functional 
recovery and infarct size). 
 
1. Ischemic control (n=6) 
 
 
 
 
 
 
2. Red wine (12%) n=6 
 
 
 
 
Group 2: Delineation of the active components in red wine (Endpoint = 
Functional recovery. 
 
 
1. Wine (6%) n=6 
 
 
 
 
 
 
 
2. Alcohol(6%) n=6 
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10 days water
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3.  Resveratrol (Res 7mg/L) n=6 
 
 
 
 
 
4. Melatonin (Mel 0.75µg/L) n=6 
 
 
 
 
 
5. Ethanolamine (Etn 21µg/L) n=6 
 
 
 
 
 
6. Pre-treatment with melatonin and ethanolamine (Mel+Etn) n=6 
 
 
 
 
 
Group 3: Role of melatonin in red wine-induced cardioprotection (Endpoint = 
functional recovery and infarct size) 
 
1. Luzindole (Luz 5mg/kg/day)  n=6 
 
 
 
 
 
10 days Res
30 min GI30 min S 60min R
10 days Mel
30 min GI30 min S 60min R
10 days Etn
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2.  Co-administration of luzindole and melatonin (Mel+ Luz) (n=6)  
 
 
 
 
 
3. Co-administration of luzindole (Luz)  and wine(n=6) 
 
 
 
 
 
Group 4: The role of STAT-3 in red wine-induced cardioprotection (Endpoint = 
Functional recovery and infarct size). 
 
 
1. AG490 (5mg/kg/day)  n=6 
 
 
 
 
 
2. Co-administration of red wine and AG490  n=6  
 
 
 
 
  
Group 5: Melatonin, ethanolamine and resveratrol protect against I/R via the 
activation of STAT-3.  
 
To explore whether ethanolamine, melatonin and resveratrol components may 
protect against I/R via the activation of STAT-3, we subjected rats to ischemia 
(RI)-reperfusion insult following an acute treatment of ethanolamine, 
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melatonin or resveratrol and the STAT-3 inhibitor, AG490. The endpoint for all 
the groups below was infarct size. 
 
 
1. Ischemic control n=6 
 
 
 
2.  Acute administration of melatonin (M 0.75µg/L) n=6 
 
 
 
 
 
3. AG490 (A 100nM)  n=6 
  
 
 
 
4. Co-administration of melatonin and AG490 (M+A)  n=6 
 
 
 
 
Group 6: The mechanism for ethanolamine-induced protection 
 
1. Acute administration of ethanolamine (E 21µg/L) n=6 
 
 
 
 
2. Administration AG490 (A 100nM) n=6 
 
 
 
30 min S
30 min RI 120min R
WB
10’ wo
30 min S
30 min RI 120min R
WB
15’ M
30 min S 30 min RI 120min R23’ A
3’A
30 min S 30 min RI 120min R
10’ wo
15’
M+A
5’A
30 min S
30 min RI 120min R
WB
15’ E
30 min S 30 min RI 120min R
10’ wo
23’ A
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 35 
3. Co-administration of ethanolamine + AG490 (E+A)  n=6 
 
 
 
The rat hearts were isolated and pre-treated either chronically or acutely with 
red wine, alcohol, resveratrol, melatonin or ethanolamine to examine the 
cardioprotective effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Pictures taken during the perfusion protocol. 
 
2.5 Infarct size 
At the end of the reperfusion period, the coronary artery was reoccluded and 
0.5 mL of 2% Evans blue was perfused slowly through the heart to delineate 
the area at risk. Hearts were frozen for 24 hours at -20° C and cut into 2 mm 
thick slices. The slices were stained and incubated in sodium phosphate 
buffer containing 1% w/v of triphenytetrazolium chloride pH7.4 at 37º C for 15 
min. Slices were fixed in 10% v/v formaldehyde solution for 24 hours for 
visualisation. Infarct and the area at risk were determined with planimetry 
(Summa Sketch ΙΙ; Summa Graphics) and infarct size was expressed as a 
percentage of the area at risk.   
 
Male Wistar Rat Isolated rat heart Temperature recorder
Hemodynamic Parameters Western Blots 
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2.6     Western Blots 
Rat hearts were harvested and perfused as previously described. The hearts 
were subjected to different acute treatments (Control, melatonin, 
ethanolamine and resveratrol) and freezed clamped prior to the index 
ischemia (after removal of atria). An additional group that was chronically pre-
treated with red wine was collected at 15 min into reperfusion, for later 
Western Blot analysis to explore the levels total and phosphorylated STAT-3 
in the heart. 
 
2.6.1 Protein extraction 
Frozen tissue was pulverized with a hammer. The powdered tissue (200mg) 
were homogenized with 900μl lysis buffer (20mM HEPES, 2.5mM MgCL2, 
100μM EDTA, 20mM β- glycerophosphate, 0.05% Triton x-100 (cytosolic 
extract), 1% Triton x-100(nuclear extract), 500μM dithiothereitol (DTT),1mM 
phenylmethylsulfonyl fluoride (PMSF) and 75mM NaCl and centrifuged at 
10000g for 5min. The supernatant (crude cytosolic extract) was removed and 
corresponded to the crude cytosolic extract. Thereafter, 500μl lysis buffer was 
added to the homogenized and centrifuged at 15000g for 30min. The 
supernatant was removed and corresponded to the crude nuclear extract. 
 
2.6.2 Protein quantification 
The Lowry Assay was used to quantify the concentration of proteins (Lowry et 
al., 1951). Bovine Serum Albumin (BSA) standard curve ranged from a 
concentration of 5-200mg/L and the absorbance was measured at 250 nm. 
 
2.6.3 SDS PAGE of extracted proteins 
Lysates were diluted in Laemmli sample buffer and boiled for 5 min. 100μg of 
proteins were separated on a 10% sodium dodecyl sulphate (SDS PAGE) gel. 
Using standard Bio-Rad Mini-PROTEAN ІІ System for two hours at 120 volts 
and transferred to nitrocellulose membrane (Amersham Bioscience Hybond 
PRPN 303F) overnight. 
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2.6.4 Immuno-blotting and detection 
The membranes were stained with a Ponceau Red stain (Ponceaus solution 
sigma, USA P7170) to check for equal loading. Membranes were blocked with 
5% milk in tri-buffered saline (TBS-Tween) (0.1% Tween) for 3 hours. The 
membranes were probed with primary antibodies phospho-STAT and total-
STAT or β-actin overnight at 4°C. The primary antibody (total STAT (H-190) 
sc-7179 Santa Cruz Biotechnology rabbit polyclonal, phospho-STAT-3 (Tyr 
705) sc-7993 Santa Cruz Biotechnology goat polyclonal, phospho-
STAT(serine 727) # 91365 Cell signaling technology, USA Mouse mAb) was 
washed off with TBS -T (0.1% Tween),3 times for 5 min, and  the membranes 
were probed with the secondary antibody (Biotechnology, Donkey anti-rabbit 
IgG-HRP sc-2313 Santa Cruz Biotechnology, USA) for 1 hour. Detection was 
accomplished with enhanced chemiluminescents (ECL).  The emission of light 
was based on the interaction between the luminol and the horse radish 
peroxides (HRP) conjugated to the secondary antibody for qualitative or semi-
quantitative analysis. Relative densitometry was determined with use of a 
computerized software package, UVIBAND.  
 
2.7 Statistical analysis 
All values are expressed as the mean ± SEM.  Multiple comparisons were 
made with one-way analysis of variance (ANOVA) followed by the post-hoc 
Tukey-Kramer. The statistical analyses were implemented in INSTAT 
programme. Statistical significance was set at *p< 0.05.  
 
2.8 Pharmacologic Agents 
Luzindole, a melatonin inhibitor was obtained from Tocris bioscience (London, 
England) and if not mentioned in the text all drugs were obtained from Sigma 
Chemicals Company (St Louis, MO, USA). 
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CHAPTER 3: RESULTS 
 
3.1 Chronic moderate consumption of red wine confers protection 
against ischemia reperfusion 
3.1.1 Effect of red wine on hemodynamic parameters 
To explore the cardioprotective effect of chronic moderate consumption of red 
wine, the isolated hearts from rats pretreated with wine for 10 days were 
exposed to 30 min global ischemia followed by 30 min of reperfusion. Pre-
treatment with red wine had no significant effect on the pre-ischemic values of 
LVDP, heart rate and coronary flow compared to the control group. After 30 
min of reperfusion, the control hearts had a LVDP of 15.3±2.4mmHg. Pre-
treatment with red wine improved LVDP to 38.0±3.0mmHg (p<0.001 vs. 
control) without any significant changes in the heart rate (HR for red wine: 
253.0±29.0 beats/min ns vs. control) nor the coronary flow (8.8±0.3mL/min vs. 
10.0±1.6mL/min ns vs. control) 
 
 Table 3: The effect of chronic red wine consumption in the isolated rat hearts subjected to 
ischemia- reperfusion 
 Hemodynamic parameters 
 Pre-ischemic  Reperfusion 5 min Reperfusion 30 min 
LVDP (mmHg)    
Control 89.3 ± 3.0 7.33 ± 2.4 15.3 ± 2.4 
Wine 94.5 ± 2.4 14.5 ± 2.6 38.0 ± 3.0*** 
Heart Rate (beats/min)    
Control 265.3 ± 52.5 200.0 ± 9.5 227.0 ± 20.0 
Wine 292.5 ± 8.7 180.1 ± 26.1 253.0 ± 29.0 
Coronary flow (mL/min)    
Control 11.60 ± 1.12 10.0 ±1.63 10.0 ±1.63 
Wine 10.0 ± 0.27 6.6 ± 0.90 8.8 ± 0.26 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5 or 30 min of reperfusion (post-ischemic). LVDP=left ventricular developed pressure, 
***p<0.001 vs. the control group at 30 min of reperfusion. 
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3.1.2 Effect of chronic moderate consumption of red wine on 
functional recovery 
After 30 min of reperfusion the control hearts had a rate pressure product 
(RPP) of 15.3±2.4% (which is expressed as a percentage of a baseline 
value). This is in accordance with findings previously described in the 
literature (Lecour et al., 2002). Pre-treatment with red wine improved the 
functional recovery of the heart to 36.9±5.0% (**p<0.01 vs. control).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: The effect of chronic to moderate consumption of red wine on rate pressure 
product (RPP), CTL: control **p<0.01.n=6 per group. 
 
 
3.1.3 Effect of chronic moderate consumption of red wine on infarct 
size  
The control hearts subjected to 30 min global ischemia followed by 60 min of 
reperfusion had an infarct size of 60.8±5.9%. Pre-treatment with red wine 
improved the infarct size to 21.5±7.8% (**p<0.01 vs. control group). 
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Figure 15: The effect of chronic to moderate consumption of red wine on infarct size. CTL: 
control, **p<0.01 n=6 per group.  
 
3.2 Delineation of the active components found in red wine 
To explore the role of alcohol in the cardioprotective effect of red wine, rats 
were pre-treated with wine 12%, wine 6% or alcohol 6% for 10 days and 
subjected to 30 min of ischemia followed by 30 min of reperfusion.  
 
3.2.1 Role of alcohol in the cardioprotective effect of red wine 
Of note, the alcohol 6% used in this study was in fact the alcohol extracted 
from the wine. Pre-treatment with wine (12%), wine (6%) or alcohol (6%) had 
no significant effect on the pre-ischemic values for LVDP, heart rate and 
coronary flow compared to the control group. After 30 min of reperfusion, the 
LVDP of wine (6%) improved to 36.6±3.0mmHg (***p<0.001 vs. control) and 
protected to a similar extent than the wine (12%). The pre-treatment with wine 
(6%) did not change heart rate (270.0±18.0 beats/min ns vs. control) or the 
coronary flow (6.9±0.3mL/min vs. 5.5±0.3mL/min).  
 
Alcohol 6% on its own, did not significantly improve LVDP at 5 min of 
reperfusion. However, after 30 min of reperfusion the LVDP of alcohol 
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improved to 26.4±2.2mmHg (** p<0.01) and there was no difference in heart 
rate or coronary flow (ns vs. control). 
 
Table 4: The effect of wine (12%), wine (6%) or alcohol (6%) on the isolated rat heart 
subjected to ischemia-reperfusion 
 
Hemodynamic parameters 
 Pre-ischemic  Reperfusion 5min Reperfusion 30min 
LVDP (mmHg) 
Control 89.3 ± 3.0 7.33 ± 2.4 15.3 ± 2.4  
Wine 94.5 ± 2.4 14.5 ± 2.6 38 ± 3.0 *** 
Wine (6%) 87.3 ± 2.0 27.0 ± 5.0 36.6 ± 3.0*** 
Alcohol  101.2 ± 5.6 33.4 ± 21.9 26.4 ± 2.2** 
Heart Rate (beats/min)  
Control 265.3 ± 52.5 200.0 ± 9.5 227.0 ± 20.0 
Wine 292.5 ± 8.7 180.1 ± 26.1 253.0 ± 29.0 
Wine (6%) 307.0 ± 13.3 260.3± 34.0  270.0 ±18.0 
Alcohol 304.6 ± 9.7 228.0 ± 26.5 280.0 ± 0.0 
Coronary Flow (mL/min)  
Control 11.60 ± 1.12 10.0 ±1.63 5.5 ± 0.3 
Wine 10.0 ± 0.27 6.6 ± 0.90 5.6 ± 0.2 
Wine (6%) 13.0 ± 1.1 7.3 ± 0.4 6.9 ± 0.3  
Alcohol 11.6 ± 0.2 9.8 ± 0.6 6.8± 0.48 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5 or 30 min of reperfusion (post-ischemic). LVDP=left ventricular developed pressure, 
HR=heart rate, CF= coronary flow **p<0.01 vs. the control group, ***p<0.001 vs. the control. 
 
3.2.1.1 Effect of wine (12%), wine (6%) and alcohol on functional 
recovery 
The treatment with wine (6%) enhanced the functional recovery compared 
with control groups (**p<0.01) and protected to a similar extent to wine 12% 
(RPP: 36.8±5.0% vs. 36.9±5.0%). Alcohol (6%) given on its own did not 
significantly improve the functional recovery after 30 min of reperfusion 
compared with control 24.3±2.3% (ns vs. control). 
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Figure 16: The role of alcohol in wine induced cardioprotection. CTL: control, wine (6%): wine 
with reduced alcohol, alc (6%): alcohol on its own from the red wine. **p<0.01 n=6 per group. 
 
3.2.2 Role of resveratrol in cardioprotective effect of red wine 
3.2.2.1 Effect of resveratrol on hemodynamic parameters 
To explore the possible contributi n of resveratrol in red wine-induced 
cardioprotection, we pretreated rats with resveratrol (7mg/L) for 10 days, a 
concentration equivalent to the concentration found in red wine.  
 
Chronic pre-treatment with resveratrol had no significant effect on the pre-
ischemic values of LVDP, heart rate and coronary flow compared to the 
control groups. After 5 min of reperfusion the LVDP improved to 
18.8±2.0mmHg (**p<0.01 compared to control). However, pre-treatment with 
resveratrol after 30 min of reperfusion did not improve the LVDP compared to 
control (16.7±2.4mmHg vs.15.3±2.4mmHg; ns vs. control). The pre-treatment 
with resveratrol did not change the heart rate during the reperfusion period 
(242±29.7beats/min ns vs. control) nor the coronary flow (10±1.63mL/min 
vs.8.2±0.86mL/min; ns vs. control). 
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Table 5: The effect of chronic pre-treatment with resveratrol on the isolated rat hearts against 
ischemia-reperfusion 
 
Hemodynamic parameters 
 Pre-ischemic  Reperfusion 5min Reperfusion 30min 
LVDP(mmHg) 
Control 89.3 ± 3.0 7.33 ± 2.4 15.3 ± 2.4 
Res 94.8 ± 3.3 18.8 ± 2.0 ** 16.7 ± 2.4 
Heart Rate(beats/min) 
Control 340.3 ± 17.0 200.0 ± 9.5 260.0 ± 8.7 
Res 304.5 ± 7.4 242.1 ± 29.7 276.0 ± 13.2 
Coronary Flow(mL/min) 
Control 11.60 ± 1.12 10.0 ± 1.63 10.0 ± 1.63 
Res  12.8 ± 0.80 10.4 ± 1.60 8.2 ± 0.86 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5min or 30 min of reperfusion (post-ischemic). Res=resveratrol LVDP=left ventricular 
developed pressure, **p<0.01 vs. the control.n=6 per group. 
 
3.2.2.2 Effect of resveratrol on functional recovery 
At the end of reperfusion period, control hearts presented a functional 
recovery of 16.4±6.4%. The pre-treatment with resveratrol did not improve the 
functional recovery compared with the controls (16.7±2.4%; ns vs. control).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 17: The effect of chronic treatment with resveratrol, with an equivalent concentration 
to that found in red wine.  CTL: control, Res: Resveratrol. n=6 per group. 
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3.2.3 Role of melatonin in red wine-induced cardioprotection 
3.2.3.1 Effect of melatonin on hemodynamic parameters 
To explore the possible contribution of melatonin in red wine induced 
cardioprotection, we pretreated rats with melatonin (0.75µg/L), for 10 days, a 
concentration was equivalent to the concentration found in red wine, and we 
subjected the hearts to 30 min of global ischemia followed by 60 min of 
reperfusion. The pre-treatment with melatonin had a significant effect after 
5min of reperfusion when compared to the control (26.0±3.0; **p<0.01). The 
pre-ischemic values for heart rate and coronary flow compared to the control 
group.  
 
After 30 min of reperfusion the LVDP improved to 27.44mmHg (**p<0.01 vs. 
control). This protection persisted at 60 min of reperfusion (34.9±5.1mmHg vs. 
16.5±3.2mmHg; **p<0.01). The pre-treatment with melatonin had no effect on 
heart rate (HR for melatonin: 286.6±16.0 beats/min ns vs. control) nor 
coronary flow before or after ischemia-reperfusion. 
 
Table 6: The effect of chronic melatonin pre-treatment in the isolated rat hearts subjected to 
ischemia- reperfusion 
Hemodynamic parameters 
 Pre-ischemic  Reperfusion 
5min 
Reperfusion 
30min 
Reperfusion 
60min 
LVDP (mmHg) 
Control 89.3 ± 3.0 7.33 ± 2.4 15.3 ± 2.4 18.0 ± 3.2 
Mel 95.9 ± 4.4 26.0 ± 3.0** 27.4 ± 5.1**  34.9 ± 5.1**  
Heart rate (beats/ min) 
Control 265.3 ± 52.5 200.0 ± 9.5 260.0 ± 8.7 268.6 ± 34.6 
Mel 268.6 ± 11.4 217.1 ±11.9 262.8 ± 34.7 286.6 ±16.0  
Coronary flow (mL/min) 
Control 11.6 ± 1.12 10.0 ± 1.63 10.0 ±1.63 10.6 ± 1.639 
Mel 10.4 ± 0.4 9.4 ± 0.5 8.6 ± 0.3 8.6 ± 0.3 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5 or 30 min of reperfusion (post-ischemic). Mel=melatonin LVDP=left ventricular developed 
pressure, **p<0.01 vs. the control group at 30 min or 60 min of reperfusion. 
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3.2.3.2 Effect of melatonin on functional recovery 
At the end of the reperfusion period control hearts presented a functional 
recovery of 16.4±6.4%. The pre-treatment with melatonin enhanced the 
functional recovery to 30.6±2.3% (**p<0.01).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: The effect of melatonin on RPP. The concentration of melatonin was equivalent to 
the concentration found in red wine. RPP: rate pressure product, CTL: control and Mel: 
melatonin **p<0.01. n=6 per group 
 
3.2.3.3 Effect of melatonin on infarct Size 
The control hearts presented an infarct size of 60.8±5.9%. The treatment with 
melatonin decreased infarct size to 27.5±7.8% (***p<0.001 vs. control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: The effect of chronic to moderate treatment with melatonin on infarct size. CTL: 
control and Mel: melatonin ***p<0.001. n=6 per group. 
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3.2.3.4 Effect of luzindole combined with wine or melatonin on 
functional recovery 
To explore the possible role of melatonin in red wine-induced 
cardioprotection, we pretreated rats with melatonin or wine in the presence of 
luzindole (5mg/kg, ip), a melatonin inhibitor, for 10 days prior to ischemia-
reperfusion. 
 
Hearts were pre-treated with luzindole alone presented a functional recovery 
of 16.0±1.0% at the end of the reperfusion period. The co–administration of 
luzindole with melatonin abolished the protective effect of melatonin 15±1.3% 
(ns vs.control). Surprisingly, the co-administration of wine and luzindole 
improved functional recovery to 40.0±1.5% (***p<0.001 vs. control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: The role of melatonin in wine induced cardioprotection. RPP: rate pressure 
product, CTL: control, Luz: luzindole; melatonin inhibitor, W+L: wine + luzindole and M+Luz: 
melatonin + luzindole ***p<0.001. n=6 per group 
 
3.2.3.5 Effect of luzindole combined with wine or melatonin on infarct 
size 
Hearts treated with chronic administration of luzindole had an infarct size of 
60.7±1.2% (ns vs. control). The co–administration of melatonin with luzindole 
abolished the protective effect and presented an infarct of (55.9±1.3%; ns vs. 
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control). However, the co-administration of wine and luzindole decreased 
infarct size to 22.0±1.3% (***p<0.001 vs. control).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: The effect of melatonin on red wine induced cardioprotection on infarct size. CTL: 
control, Wine + Luz: wine + luzindole, Luz: luzindole, Mel + Luz: melatonin + luzindole 
***p<0.001. n=6 per group.      
 
3.2.4 Role of ethanolamine in the cardioprotective effect of red wine  
3.2.4.1 Effect of ethanolamine on hemodynamic parameters 
To explore the role of ethanolamine as a cardioprotective agent in red wine, 
rats were pre-treated for 10 days with ethanolamine (21µg/L), a concentration 
equivalent to the concentration found in French red wine. The control hearts 
presented an LVDP of 15.3±2.4mmHg after an I/R insult. Pre-treatment with 
ethanolamine did not change pre-ischemic values for LVDP, heart rate and 
coronary flow compared to control. The pre-treatment with ethanolamine 
improved LVDP at 60 min of reperfusion to 33.5±6.0mmHg (**p<0.01 vs. 
control). Interestingly, the combination of melatonin and ethanolamine 
increased LVDP at 60 min of reperfusion to 38.3±6.8mmHg (**p<0.01 vs. 
control). The pre-treatment with ethanolamine alone, or a combination with 
melatonin, had no effect on heart rate (ns vs. control) or coronary flow 
throughout the protocol (ns vs. control).  
 
CTL Mel+Luz
60
50
40
30
20
10
0
In
fa
rc
t 
s
iz
e
(%
)
Wine+Luz
***
Luz
In
fa
rc
t 
s
iz
e
(%
)
In
fa
rc
t 
s
iz
e
(%
)
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 48 
Table 7: The effect of ethanolamine and a combination of ethanolamine and melatonin 
consumption in the isolated rat hearts subjected to ischemia reperfusion 
 
Hemodynamic parameters 
 Pre-ischemic  Reperfusion 
5min 
Reperfusion 
30min 
Reperfusion 
60min 
LVDP(mmHg) 
Control 89.3 ± 3.0 7.33 ± 2.4 15.3 ± 2.4 16.0 ± 3.2 
Etn  98.6 ± 4.2 15.3 ± 5.3 24.6 ± 7.0 33.5 ± 6.0** 
Mel+Etn 89.3 ± 4.2 20.6 ± 6.9 28.0 ± 6.3 38.3 ± 6.8*** 
Heart rate(beats/min)  
Control 265.3 ± 52.5 200.0 ± 9.5 260.0 ± 8.7 260.0 ± 35.4 
Etn  286.6 ± 19.0 206.0 ± 41.7  280.0 ± 40.0 286.6 ±16.0  
Mel+Etn 280.0 ± 25.3 253.3 ± 22.1 226.4 ± 8.4 300.0 ± 26.8 
Coronary flow(mL/min) 
Control 11.60 ±1.12 10.0 ±1.63 10.0 ±1.63 10.6 ±1.639 
Etn  10.3 ± 0.3 8.3 ± 0.3 8.0 ± 0.0 8.0 ± 0.0 
Mel+Etn 10.6 ± 0.42 10.0 ± 0.0 8.3 ± 0.5 9.0 ±1.1 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5 min or 30/60 min of reperfusion (post-ischemic). Etn=ethanolamine Mel+Etn=melatonin 
and ethanolamine LVDP=left ventricular developed pressure, **p<0.01, ***p<0.01 vs. the 
control at 60 min of reperfusion n=6 per group. 
 
3.2.4.2 Effect of ethanolamine on functional recovery 
At the end of the reperfusion control hearts presented a functional recovery of 
16.4±6.4%. The pre-treatment with ethanolamine improved functional 
recovery to 28.5±2.7% (**p<0.01 vs. control). Interestingly, the combination of 
ethanolamine and melatonin further enhanced the functional recovery to 
40.0±2.6% (***p<0.001). 
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Figure 22: The effect of ethanolamine or its combination with melatonin on RPP. RPP: rate 
pressure product, CTL: control, Etn: ethanolamine, Etn+Mel; ethanol and melatonin. **p<0.01 
and ***p<0.001 vs. CTL. n=6 per group. 
 
3.2.4.3 Effect of ethanolamine on infarct size 
Control hearts presented an infarct size of 60.8±5.9%. The pre-treatment with 
ethanolamine for 10 days improved functional recovery to 22.6±5.7% 
(***p<0.001 vs. control). Interestingly, the combination of ethanolamine and 
melatonin further enhanced the protection and decreased the infarct size to 
5.8±1.6% (***p<0.001 vs. control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: The effect of ethanolamine or its combination with melatonin on infarct size, CTL: 
control, Etn: ethanolamine, Etn+Mel; ethanolamine and melatonin.
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3.2.5 Role of STAT-3 in red wine-induced cardioprotection 
To explore whether the cardioprotective signal transducer and activator of 
transcription (STAT-3) may be involved in red wine-induced cardioprotection, 
rats were treated with AG490 (5mg/kg/day; ip) a STAT-3 inhibitor for 10 days, 
alone or in combination with treatment of red wine. 
 
3.2.5.1 Effect of the co-administration of red wine and AG490, a STAT-3 
inhibitor, on hemodynamic parameters 
The pre-treatment with AG490 or the combination of wine and AG490 did not 
alter the pre-ischemic values for LVDP, heart rate and coronary flow 
compared to controls. Hearts that were pre-treated with red wine and AG 490, 
the STAT-3 inhibitor had a LVDP of 14.7±1.7mmHg at 60 min of reperfusion 
(ns vs. control). The pre-treatment with AG490, or a combination of wine and 
AG490, had no effect on heart rate (ns vs. control) nor in coronary flow (ns vs. 
control).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 51 
Table 8:  Role for STAT-3 in wine-induced cardioprotection in the isolated rat heart subjected 
to ischemia-reperfusion 
Hemodynamic parameters 
 Pre-ischemic  Reperfusion 
5min 
Reperfusion 
30min 
Reperfusion 
60min 
LVDP(mmHg) 
Control 89.3 ± 3.0 7.3 ± 2.4 15.3 ± 2.4 16.5 ± 3.2 
Wine 94.5 ± 2.4 14.5 ± 2.6** 38.0 ± 3.0 39.1 ± 3.3*** 
AG490 93.3 ± 3.8 7.3 ± 2.3 10.6 ± 1.7 10.6 ± 1.7 
Wine+AG490 96.6 ± 1.3 4.0 ± 1.4 9.3 ± 0.8 14.7 ± 1.7 
Heart Rate(beats/min) 
Control 265.3 ± 52.5 200.0 ± 9.5 260.0 ± 8.7 286.6 ± 16.0 
Wine 292.5 ± 8.7 180.1 ± 26.1 290.0± 13.4 317.5 ± 9.3 
AG490 320.0 ± 27.3 173.3± 77.4  273.3 ± 49.9 360.0 ± 27.3 
Wine+AG490 296.6 ± 48.0 160.0 ± 52.6 226.0 ± 16.8 306.0 ± 16.8 
Coronary Flow(mL/min) 
Control 11.6 ± 1.1 10.0 ± 1.6 10.0 ± 1.6 10.6 ± 1.6 
Wine 10.0 ± 0.3 6.6 ± 0.9 8.8 ± 0.3 8.9 ± 0.3 
AG490 10.3 ± 0.3 8.3 ± 0.3 8.0 ± 0.0 8.0 ± 0.0 
Wine+AG490 10.0 ± 0.1 6.0 ± 1.9 8.6± 0.4 8.6 ± 0.4 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5min or 30/60 min of reperfusion (post-ischemic). Wine = Wine (2 glasses/day), AG490=a 
STAT-3 inhibitor, wine+AG= co-administration of wine and AG LVDP=left ventricular 
developed pressure **p<0.01 vs. the control group, ***p<0.01 vs. control. n=6 per group. 
 
3.2.5.2 Effect of the co-administration of red wine and AG490, a STAT-
3 inhibitor, on hemodynamic parameters  
Hearts pre-treated with AG490 presented a functional recovery of 11.4±3.1% 
at the end of reperfusion period (ns vs. control).  Interestingly, the combination 
of wine and AG490 abolished the protective effect of red wine on functional 
recovery (14.4 ± 2.9; ns vs. control). 
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Figure 24: The effect of red wine in the presence of AG490; a STAT-3 inhibitor on RPP. RPP; 
rate pressure product, CTL: control, AG: AG490, Wine+AG: wine + AG490 ***p<0.001 vs. 
control. n=6 for per groups. 
  
3.2.5.3 Effect of the co-administration of red wine and AG490, a STAT-
3 inhibitor, on infarct size 
Hearts pre-treated with AG490 for 10 days presented an infarct size of 
60.9±7.3% (ns vs. control). However, the co-treatment of red wine with AG490 
abolished the infarct-sparing effect of red wine to (57.9±3.4%; ns vs. control). 
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Figure 25: The effect of red wine in the presence or the absence of AG490; a STAT-3 
inhibitor on infarct size. CTL: control, AG: AG490, W+AG: wine + AG490 **p<0.01 vs. control. 
n=6 per group 
  
3.2.5.4 Levels of pSTAT-3 after chronic and moderate consumption of 
red wine 
To investigate the role of STAT-3 in red wine-induced cardioprotection, we 
measured the levels of phosphorylated STAT-3 in rat hearts pre-treated with 
red wine and subjected to 30 min global ischemia and 15 min of reperfusion.  
The graph below shows that the pre-treatment with red wine increased STAT-
3 phosphorylation in both the cytosol (0.5±0.2 A.U; *p<0.05 vs. control) and 
the nucleus (**p<0.01 vs. control).  
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Figure 26: The effect of red wine on levels of pSTAT-3/Total STAT-3 in the cytosol and in the 
nucleus pSTAT:phosphorylated STAT, tSTAT: total STAT. *p<0.05 **p<0.01 vs. control. n=4 
per groups. 
 
 
3.2.6 Role of ethanolamine in wine induced cardioprotection  
To explore whether ethanolamine, melatonin and resveratrol may protect 
against I/R via the activation of STAT-3, we subjected rats to an acute 
treatment of ethanolamine, melatonin or resveratrol with/without AG490, a 
STAT-3 inhibitor before being subjected to 30 min of regional ischemia and 
120 min of reperfusion (all drugs were given directly to the perfused heart). 
 
3.2.6.1 Effect of the co-administration of ethanolamine and AG490, 
a STAT-3 inhibitor, on  hemodynamic parameters 
The pre-treatment with ethanolamine, AG490 or the combination of 
ethanolamine and AG490 prior to the ischemia reperfusion insult had no 
significant effect on both the pre-ischemic and post ischemic values. 
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Table 9: Role for STAT-3 in ethanolamine induced cardioprotection in the isolated rat heart 
subjected to ischemia-reperfusion. 
Hemodynamic parameters 
 Pre-
ischemic  
Ische mic Reperfusion 
5min 
Reperfusion 
30min 
Reperfusion 
60min 
Reperfusion 
120min 
LVDP (mmHg) 
Control 95.0 ± 4.4 52.4 ± 5.5 65.2 ± 6.8 62.2 ± 6.0 54.4 ± 4.4 44.8 ± 5.7 
Etn 90.9 ± 3.0 41.7 ± 6.3 56.0 ± 6.4 45.7 ± 3.5 38.6 ± 4.3 35.1 ± 3.4 
Etn+AG4
90  
89.0 ± 3.2 43.0 ± 4.6 67.3 ± 4.1 56.6 ± 6.6 53.3 ± 4.0 53.0 ± 8.0 
AG490 92.6 ± 4.0 38.6 ± 2.6 53.1 ± 6.3 53.1 ± 6.3 46.3 ± 5.4 40.0 ± 3.8 
Heart Rate (beats/min) 
Control 348 ± 6.1 308 ± 12.0 312 ± 10.0 308 ± 10.4 292 ± 14.7 292 ± 14.7 
Etn 314.0 ± 10.4 268.6 ± 11.4 285.7 ± 18.4 297.1 ± 4.8 297.1 ±14.8 308.6 ± 14.2 
Etn+AG4
90 
326.6 ± 16.0 333.3 ±  8.4 320.0 ± 20.7  313.0 ±19.0 306.7 ± 22.3 367 ± 24.6 
AG490 320.0 ± 21.4 302.9 ± 24.5 274.3 ± 28.1 291.4 ± 24.2 302.9 ± 22.9 302.9 ± 19.2 
Coronary Flow (mL/min) 
Control 11.6 ± 0.6 7.0 ± 0.7 11.2 ± 0.7 12.4 ± 0.6 10.6 ± 0.9 10.0 ± 0.9 
Etn 11.4 ± 0.4 7.4 ± 0.8 11.4 ± 0.4 10.6 ± 0.7 10.6 ± 0.7 8.9 ± 0.9 
Etn+AG4
90 
12.7 ± 1.2 8.3 ± 1.7 10.8 ± 1.0 11.0 ± 1.5 11.7 ±1.2 8.0 ± 1.7 
AG490 11.4 ± 0.57 8.0 ± 0.7 11.5 ± 0.4 11.1 ± 0.6 11.1 ± 0.6 9.4 ± 0.7 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 5 or 30-120 min of reperfusion (post-ischemic). Etn= Ethanolamine, AG490=a STAT-3 
inhibitor, Etn+AG= co-administration of ethanolamine and AG490 LVDP=left ventricular 
developed pressure, HR=heart rate, CF= coronary flow ns vs. the control group at 120 min of 
reperfusion.n=6 per group. 
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3.2.6.2 Effect of the co-administration of ethanolamine and AG490 on 
infarct size  
The control hearts presented an infarct size of 39.9±10.7%. The acute 
administration of ethanolamine before ischemia improved infarct size 
compared to the control (***p<0.001 vs. control). AG490 on its own did not 
change infarct size compared with the control group (33.9 ± 8.7%; ns vs. 
control). However, the co-administration of ethanolamine with AG490 
abolished the infarct sparing effect of ethanolamine (36.8 ±8.7%; ns vs. 
control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: The effect of ethanolamine with or without the STAT-3 inhibitor AG490 on infarct 
size. CTL= Control, Etn= Ethanolamine, Etn+AG=Ethanolamine+STAT-3 inhibitor, 
AG=AG490 ***p<0.001. n=6 per group. 
 
3.2.6.3 Levels of pSTAT-3 after a pre-treatment of ethanolamine     
The hearts were pre-treated with ethanolamine for 15 min followed by a 10 
min wash out and were collected before index ischemia to investigate STAT-3 
phosphorylation. The graph below shows that the pre-treatment with 
ethanolamine decreased STAT-3 phosphorylation in the cytosol (0.5±0.2 A.U; 
**p<0.01 vs. control). However, there was a 57% increase of pSTAT in the 
nucleus (***p<0.01 vs. control).  
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Figure 28: The effect of Etn on Phospho STAT-3/Total STAT-3 in the cytosol or the nucleus 
with Etn. CTL: control, Etn: ethanolamine, pSTAT: phosphorylated STAT, tSTAT: total STAT 
**p <0.01, ***p<0.001. n=4 for all groups. 
 
3.2.7 Role of STAT-3 in melatonin induced cardioprotection  
3.2.7.1 Effect of the co-administration of melatonin and AG490, a 
STAT-3 inhibitor on hemodynamic parameters 
  To explore whether melatonin protects against I/R via the activation of 
STAT-3, we subjected the hearts to an acute treatment of melatonin 
with/without AG490, a STAT-3 inhibitor before 30 min of regional ischemia 
and 120 min of reperfusion. 
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Table 10:  Role for STAT-3 in melatonin induced cardioprotection in the isolated rat heart 
subjected to ischemia-reperfusion. 
 
Hemodynamic parameters 
 Pre-
ischemic  
Ischemic Reperfusion 
5min 
Reperfusion 
30min 
Reperfusion 
60min 
Reperfusion 
120min 
LVDP(mmHg) 
Control 97.0 ± 6.9 49.3 ± 7.5 58.2 ± 7.8 56.3 ± 5.0 52.6± 4.9 44.6 ± 6.6 
Mel 101.3 ± 4.3 71.3 ± 17.3 101.3± 36.4 86.0 ± 15.6 75.3 ± 18.3 71.3 ± 19.0 
Mel + 
AG490 
94.3 ± 5.2 65.7 ± 24.4 50.3 ± 12.5 55.1 ± 14.6 40.0 ±11.6 34.9 ± 10.5 
AG490 99.3 ± 3.9 52.3 ± 6.2 63.1 ± 5.3 65.5 ± 5.1 52.0 ±5.6 50.0 ± 5.9 
Heart rate (beats/min) 
Control 340 ± 13.6 320 ± 17.9 313 ± 19.1 320± 10.3 306.6±16.9 300± 22.5 
Mel 300.0 ± 13.3 240.0 ±17.9 213.3 ±19.7 213.1 ±19.7 240.1 ±34.3 276.6 ±30.3 
Mel+AG
490 
268.6 ± 13.6 240.3 ± 17.8 222.9 ±19.7  234.0 ±34.3 211.4 ±43.4 200±41.8 
AG490 305.0 ± 21.3 275.0 ± 27.7 260.0 ±23.9 280.4 ±26.2 275.0 ±26.6 275.0 ±26.6 
Coronary flow (mL/min) 
Control 11.0 ±0.7 8.3.0 ±0.7 8.3 ±2.1 9.6 ±1.3 9.3 ±0.9 11.0 ±0.9 
Mel 11.0 ±0.4 9.0 ±0.7 9.6 ±0.6 10.3 ±0.6 10.3 ±0.6 10.3 ±0.6 
Mel+AG
490 
10.9 ±1.4 9.5 ±0.4 8.9±0.4 9.4 ±0.4 8.9 ±0.6 8.9 ±0.6 
AG490 11.8 ± 0.3 9.0 ± 0.5 11.0 ±0.5 11.1 ±0.5 11.1 ±0.6 10.0 ±0.7 
Parameters measured prior to ischemia (pre-ischemic), parameters measured after ischemia 
at 30 min of reperfusion (post-ischemic). Mel= melatonin, AG490=a STAT-3 inhibitor, 
Mel+AG= co-administration of melatonin and AG490. LVDP=left ventricular developed 
pressure, HR=heart rate, CF= coronary flow. All groups ns vs. the control group at 120 min of 
reperfusion 
 
3.2.7.2 Effect of the co-administration of  melatonin and AG490, a 
STAT-3 inhibitor on infarct size  
The control hearts presented an infarct size of 44.4±2.8%. Administration of 
melatonin reduced infarct size to 25.0±2.9% (**p<0.01 vs. control). AG490 on 
its own did not change infarct size 33.9±8.7% compared to the control group 
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(ns vs. control). However, the co-administration of melatonin with AG490 
abolished the infarct sparing effect of melatonin (36.83 ±8.7; ns vs. control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: The effect of melatonin with or without AG490 on infarct size. AG: AG490 and Mel 
+ AG: melatonin + AG490 ***p<0.001. n=6 per group. 
 
3.2.7.3 Levels of pSTAT-3 after a pre-treatment with melatonin            
The hearts were pre-treated with melatonin for 15 min followed by a 10 min 
wash-out and were collected before index ischemia to investigate STAT-3 
phosphorylation. The graph below shows that the pre-treatment with 
melatonin had no effect on STAT-3 phosphorylation in the cytosol (ns vs. 
control). In the nucleus there was a 79% increase of pSTAT (***p<0.01 vs. 
control).  
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Figure 30: The effect of melatonin on Phospho STAT-3/Total STAT-3 in cytosol or nucleus. 
CTL: control, Mel: melatonin, pSTAT: phosphorylated STAT, tSTAT: total STAT **p<0.01. n=4 
for all groups. 
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CHAPTER 4: DISCUSSION AND CONCLUSIONS 
 
4.1. Summary of results 
The aim of our study was to examine whether chronic moderate consumption 
of red wine equivalent to 2-3 glasses per day could protect isolated rat hearts 
from ischemia-reperfusion injury and to identify the cardioprotective 
components which are found in red wine and which are responsible for its 
cardioprotective effect.   
 
In this study, we have shown that the chronic and moderate consumption of 
red wine for 10 days has the ability to protect the heart against ischemia-
reperfusion. Our study did not support the statement that alcohol and 
resveratrol contribute to the cardioprotective effect of red wine. Hence, a 
chronic treatment with either alcohol or resveratrol, given at the concentration 
equivalent to the concentration found in red wine did not protect the heart 
against ischemia-reperfusion.  
 
However, our results show for the very first time to our knowledge, the 
presence of two key biogenic amines in red wine that may contribute to the 
cardioprotective effect of wine. A chronic moderate treatment with either 
melatonin or ethanolamine for 10 days, given at the concentration found in red 
wine, protected the heart against ischemia-reperfusion to a similar extent to 
red wine itself.  
 
Furthermore, our data suggest that red wine and its cardioprotective 
components (melatonin and ethanolamine) protect the heart via the activation 
of the JAK/STAT-3 pathway. 
 
4.2. Red wine can protect isolated rat heart against ischemia-
reperfusion.  
Chronic moderate consumption of red wine is thought to contribute to 
cardioprotection and many experimental studies using the isolated rat heart 
models have explored the role of red wine against ischemia-reperfusion. 
However, all these studies were performed by giving acutely either red wine 
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polyphenols extracts (Das et al. 1999, Fuhrman et al. 2001) or some 
components of the wine such as resveratrol or ethanol (Ray et al. 1999a). At 
the time we started this study, no previous study had given an oral 
administration of red wine (12% or 6%) to study its cardioprotective effect. 
The other components besides the alcohol content of the wine 6% were not 
altered. In our experiments, rats were pre-treated for 10 days with a French 
Carbernet Sauvigonon. The red wine was diluted into the drinking water to an 
equivalent of 2 glasses of red wine per day. This protocol originally used by 
Wollny and Collaborators successfully prevented thrombosis in rats (Wollny et 
al. 1999). Our data show that the red wine treatment improved the functional 
recovery and decreased the infarct size in hearts subjected to an ischemia-
reperfusion insult.  
 
Recently, a study performed by Das’s group demonstrated that rats pre-
treated for 14 days with red wine (Reunite Lambrusco) by gavage (6.5mg/kg), 
were protected against an ischemia-reperfusion (Dudley et al. 2008, 
Mukherjee et al. 2009). It would be of interest to compare whether the same 
wine, given chronically either by gavage or just diluted in the drinking water 
could confer a similar protection.  
 
4.3. Role of alcohol in red wine-induced cardioprotection 
Alcohol is thought to contribute to the cardioprotective effect of red wine 
against ischemia-reperfusion injury but no study has been able to compare 
the wine and its alcohol content together. Here, we were able to compare the 
wine 12% with the same wine after the removal of 6% alcohol (with no 
alteration of other components in the wine). Alcohol 6% was also 
administered on its own, and this alcohol corresponded to the alcohol 
removed from the wine directly (the alcohol in wine contains ethanol and other 
types of alcohol). Interestingly, the wine 12% and 6% protected to a similar 
extent while alcohol 6% did not protect, therefore suggesting alcohol does not 
play a role in the cardioprotective effect of red wine.  
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Recent studies have shown that mice treated with 10% alcohol for 12 weeks 
protected the hearts against ischemia reperfusion injury (Zhou, Karliner & 
Gray 2002a, Collins et al. 2009). Similarly, rats that were treated with 18% 
alcohol for 8 weeks in drinking water improved post-ischemic systolic and 
diastolic pressure and it also reduced cardiovascular resistance via the 
activation of PKCε, see review (Collins et al. 2009). However, in our study the 
chronic moderate consumption of alcohol (6%) for 10 days at the 
concentration found in wine did not improve the functional recovery or the 
infarct size. Perhaps if the pre-treatment of alcohol was extended over a 
longer period of time or if the concentration of alcohol was increased to 12%, 
cardioprotection may have occurred. However, data strongly suggest a 
cardioprotective effect of red wine beyond alcohol.  
 
4.4. Role of resveratrol in red wine-induced cardioprotection 
In the literature, numerous studies have demonstrated that an acute 
administration of resveratrol at 10µM provided cardioprotection against an 
ischemia-reperfusion insult, as evidenced by improved postischemic 
ventricular recovery, reduced infarct size and decreased cardiomyocytes 
apoptosis (Hattori et al. 2002).   
 
Although we have been able to reproduce this cardioprotective effect in our 
laboratory when resveratrol was given at this concentration and acutely, we 
have not been able to protect the heart when resveratrol was given 
chronically, at a concentration similar to the concentration found in 2 glasses 
of wine per day. No previous studies have explored the cardioprotective effect 
of a chronic administration of resveratrol against ischemia-reperfusion. The 
concentration given chronically was 3.8µM in the drinking water. Although the 
bioavailability of resveratrol is unknown, it is reasonable to suggest that the 
concentration of resveratrol after 2 glasses of wine is much lower than 
2.3mg/L. The difference in concentrations between the acute and the chronic 
studies is therefore likely to explain why resveratrol can protect acutely but not 
chronically.  
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As a consequence, our data do not support the fact that resveratrol 
contributes to the cardioprotective effect of red wine. 
 
 
4.5. Role of melatonin in red wine-induced cardioprotection 
Interestingly, Guerrero et al. demonstrated that serum melatonin was 
significantly increased in humans, one hour after an intake of 100 mL of red 
wine and that the mean quantity of melatonin in red wine was 0.75µg/L 
(Guerrero et al., 2008).  
 
In previous studies, melatonin was administered acutely in an isolated rat 
heart preparation. The concentration of melatonin ranged from 1 to 50µM, 
which corresponded too much higher concentrations than the concentration of 
melatonin found in chronic moderate consumption of red wine (Tan et al. 
1998). In our experiments, an acute administration of melatonin, given at 
concentration of 0.75µM was enough to improve the functional recovery and 
reduce the infarct size in isolated hearts subjected to an ischemia-reperfusion 
insult.  
The long-term effects of melatonin were evaluated 24 hours after melatonin 
administration (2.5 or 5.0 mg/kg, ip) or after the oral supplementation of 
melatonin in the drinking water (20 or 40µg/mL) (Lochner et al. 2006). In our 
study, a chronic pre-treatment of melatonin protected the heart against 
ischemia-reperfusion. The final concentration of melatonin in the drinking 
water was equivalent to 0.94µg/L, which is far lower than the 40 µg/mL 
administered in previous studies.  
Luzindole, a non-selective competitive melatonin receptor antagonist, did not 
protect the heart when given alone. Co-administration of luzindole and 
melatonin abolished the protective effect of melatonin against ischemia-
reperfusion, therefore suggesting that the protective effect of melatonin is 
dependent on the activation of its receptors.  
However, we were surprised to observe that wine-induced cardioprotection 
was not abolished in the presence of luzindole. Instead, the protective effect 
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of wine was further enhanced. Luzindole is a non selective inhibitor which 
binds to melatonin receptor 1 and 2 but not receptor 3. Inhibiting the binding 
of melatonin to its receptor may lead to the accumulation of endogenous 
melatonin in the cells. Despite this excess, some of the melatonin may 
compete to bind to receptor 3, thereby conferring protection. We speculate 
that the remaining melatonin in the cell may interact with the red wine 
administered; therefore, increasing the antioxidant activity which may result in 
enhanced cardioprotection.  
 
Another explanation for the accrued protective effect of red wine with 
luzindole may be the fact that luzindole itself possesses antioxidant properties 
(Mathes, Wolf & Rensing 2008). 
 
4.6. Role of ethanolamine in red wine-induced cardioprotection 
The novel compound ethanolamine has never been studied in the setting of 
ischemia-reperfusion in the heart. Using the isolated rat heart model, our 
novel data demonstrate for the first time that the acute administration of 
ethanolamine, a component found in wine and food products can reduce 
infarct size and mediate cardioprotection against ischemia-reperfusion insult. 
The chronic pre-treatments of ethanolamine, given at a concentration 
equivalent to 2 glasses of red wine per day, protected the isolated heart 
against ischemia-reperfusion. The final concentration of ethanolamine in the 
drinking water was 2.6µg/mL. 
 
Interestingly, the co-administration of melatonin and ethanolamine, given at 
concentration similar to the concentrations found in red wine, had an additive 
effect and protected the heart against ischemia reperfusion injury by 
improving functional recovery and decreasing infarct size to a better extent 
than wine on its own. These data led us to suggest the presence of other 
protective as well as harmful components present in red wine which intuitively 
counter regulates each other. 
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4.7. Red wine-induced cardioprotection via the JAK/ STAT-3 pathway  
 Red wine and it major components alcohol, resveratrol, melatonin and 
ethanolamine are generally thought to protect against ischemia-reperfusion 
via their powerful antioxidant properties. Here, we have delineated a novel 
prosurvival pathway that can be activated within the heart by chronic 
moderate consumption of red wine. Our data suggest that this pathway is 
activated in the red wine by melatonin and ethanolamine as the two 
components were able to activate STAT-3 and their cardioprotective effect 
was lost in the presence of the STAT-3 inhibitor, AG490. The melatonin 
receptor and the JAK/STAT pathway may be stimulated by TNF (Xuan et al. 
2001, Lecour et al. 2005a) and  possible downstream targets may lead to the 
inactivation of pro-apoptotic factors such as Bax and Bad and enhances the 
activation of Bcl-2 see review (Lecour 2009a, Lecour 2009b).  However, the 
role of STAT-3 in melatonin- and ethanolamine-induced cardioprotection has 
been studied after an acute treatment of these biogenic amines in the isolated 
heart. Further experiments will be required to confirm that a chronic 
administration of ethanolamine and/or melatonin protects via the activation of 
STAT-3. 
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Figure 31: The key components of red wine that may be individually or cordially implicated in 
red wine induced cardioprotection.  
 
 
4.8. Future implications and limitations of the study 
Our study was performed on a French red Cabernet Sauvignon. It would be of 
interest to test whether wines from another grape variety or another country 
(such as South Africa) would confer a similar protective effect. 
 
Also, an important limitation of our study is the fact that we were unable to 
quantify the exact concentrations of melatonin, resveratrol and ethanolamine 
in the wine that we have used. The concentrations that we had chosen 
corresponded to the mean concentrations in red wine reported in the 
literature. We are hoping to obtain the exact concentrations of melatonin and 
ethanolamine in a near future. 
 
In addition, it would be of interest to repeat our experiments using an in vivo 
model of ischemia-reperfusion as the isolated heart system does not take into 
account the role of the blood and other organs.  
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Similarly, repeating our experiments in cardiomyocyte specific STAT-3 
deficient mice would be useful to confirm the role of STAT-3 in red wine-
induced cardioprotection. Preliminary experiments that we have performed in 
the laboratory have shown that STAT-3 knockout mice failed to be protected 
with resveratrol or ethanolamine. 
 
Finally, measuring STAT-3 activation in humans following a chronic moderate 
consumption of red wine would be of interest to confirm our statements. 
 
4.9. Conclusion 
In conclusion, our data suggest for the first time that melatonin and 
ethanolamine account for the cardioprotective effect of chronic moderate 
consumption of red wine against an ischemia-reperfusion insult and this effect 
is mediated via the activation of STAT-3. Our data provide a novel opportunity 
for the development of new therapeutic drugs against ischemic heart disease. 
In addition, the use of red wine or melatonin as a therapeutic approach 
against heart disease is facilitated by the fact that they are natural compounds 
freely available in most countries. 
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APPENDICES: SOLUTIONS AND BUFFERS 
 
1. HEMODYNAMIC PARAMETERS OF ISOLATED PERFUSED RAT 
HEARTS  
1.1. KREBS HENSELEIT BUFFER FOR LANGENDORFF PERFUSION (5L) 
NaCl               34.63g 
NaHCO3                    10.5g 
Glucose               10.99g 
KCl                 1.77g 
MgSO4.7H2O               1.47g 
KH2 PO4                   0.8g 
CaCl2.2H2O           1g 
                                                                                                                                                                                                                                                                                                                                                                                                                              
2. SOLUTIONS AND BUFFERS FOR PROTEIN EXTRACTION AND 
QUANTIFICATION 
 
2.1. PROTEIN EXTRACTION 
2.1.1. LYSIS BUFFER FOR PKB/IRSI (30ml) 
Tris-HCl, pH 7.4; EGTA                 3ml 
HEPES (20mM)               1.8ml 
EDTA (100µM)               600µl 
β-glycerophosphate (20mM)                 6ml 
NaCl (75mM)          0.1125ml 
PMSF (1mM)                  60µl 
DTT (0.5mM)               1.5ml 
Triton X-100 (0.05% - cytosolic)               45µl 
Triton X-100 (100% - nuclear)               10ml 
                                                                           
2.2. PROTEIN QUANTIFICATION 
2.2.1. CTC REAGENT FOR PROTEIN ASSAY  
(a) Na2CO3                        20g 
(b) CuSO4.5H2O                  0.2g 
K2 Tatrat                                                                                                                     
Add dH2O up to 100ml for both (a) and (b) separately   
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Add (a) to (b) slowly, while mixing to prevent precipitation. 
 
2.2.2. 10% SDS  
SDS                     20g 
Add dH2O up to 200ml           
 
2.2.3. 0.2M NaOH  
NaOH                                                                                                          0.4g 
Add dH2O up to 200ml  
 
3. SOLUTIONS AND BUFFERS FOR SODIUM DODECYL SULPHATE 
POLYACRLAMIDE GEL ELECTROPHORESIS (SDS PAGE) 
3.1. 10% SDS  
SDS                                                                                                              20g 
Add dH2O up to 200ml           
 
3.2. 10% AMMONIUM PERSULPHATE (APS) 
APS                                                                                                              20g 
Add dH2O up to 200ml 
 
3.3. 3X Laemeli (loading buffer) 
Tris                                                                                                            3.03g 
SDS                                                                                                             8.8g 
Glycerol                                                                                                       20g 
Bromophenol Blue                                                                                 0.025g 
Na in ddH2O                                                                                               75ml 
Adjust pH to 6.6 with HCl 
Add 150µl of β-mercaptoethanol in 850µl of the above solution 
 
3.4. 10X Running (Tank) buffer  
Tris                                                                                                            60.6g 
Glycine                                                                                                       288g 
SDS                                                                                                              20g 
Add dH2O up to 2L 
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3.5. 10% Resolving gel 
dH2O                                                                                                          9.8ml 
1.5M Tris-HCl, pH 8.8                                                                                  5ml 
20% SDS                                                                                                   100µl 
Acrylamide                                                                                                  5ml 
10% APS                                                                                                   100µl 
TEMED                                                                                                        40µl 
 
3.6. 10% Stacking gel 
dH2O                                                                                                          7.5ml 
0.5M Tris-HCl, pH 8.8                                                                                  3ml 
20% SDS                                                                                                     60µl 
Acrylamide                                                                                               1.5ml 
10% APS                                                                                                     30µl 
TEMED                                                                                                        40µl 
 
4. SOLUTIONS AND BUFFERS FOR WESTERN BLOTTING AND 
IMMUNODETECTION 
4.1. Transfer buffer  
Tris                                                                                                            6.06g 
Glycine                                                                                                      28.8g 
20% methanol                                                                                          400ml 
Add dH2O up to 1L 
 
4.2. 10X Tris-buffered saline (TBS) 
Tris                                                                                                            48.4g 
Dissolve in 500ml dH2O and adjust pH to 7.6 by adding HCl 
NaCl                                                                                                            160g 
Add dH2O up to 2L 
 
4.3. TBS-Tween 20 (0.01%) 
Tween 20                                                                                                      1ml 
TBS                                                                                                         1000ml 
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4.4. Blocking solution (5% milk powder) 
Powdered milk                                                                                              5g 
TBS solution                                                                                            100ml 
 
 
 
 
